0001193125-19-238855.txt : 20190905 0001193125-19-238855.hdr.sgml : 20190905 20190905161904 ACCESSION NUMBER: 0001193125-19-238855 CONFORMED SUBMISSION TYPE: N-CSRS PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190905 DATE AS OF CHANGE: 20190905 EFFECTIVENESS DATE: 20190905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gabelli Healthcare & WellnessRx Trust CENTRAL INDEX KEY: 0001391437 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: N-CSRS SEC ACT: 1940 Act SEC FILE NUMBER: 811-22021 FILM NUMBER: 191077416 BUSINESS ADDRESS: STREET 1: ONE CORPORATE CENTER CITY: RYE STATE: NY ZIP: 10580-1422 BUSINESS PHONE: 914-921-5100 MAIL ADDRESS: STREET 1: ONE CORPORATE CENTER CITY: RYE STATE: NY ZIP: 10580-1422 FORMER COMPANY: FORMER CONFORMED NAME: Gabelli Global Healthcare & WellnessRx Trust DATE OF NAME CHANGE: 20070227 N-CSRS 1 d786930dncsrs.htm GABELLI HEALTHCARE & WELLNESSRX TRUST Gabelli Healthcare & WellnessRx Trust

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT

INVESTMENT COMPANIES

Investment Company Act file number            811-22021            

                    The Gabelli Healthcare & WellnessRx Trust                    

(Exact name of registrant as specified in charter)

One Corporate Center

Rye, New York 10580-1422

 

(Address of principal executive offices) (Zip code)

Agnes Mullady

Gabelli Funds, LLC

One Corporate Center

Rye, New York 10580-1422

 

(Name and address of agent for service)

Registrant’s telephone number, including area code:  1-800-422-3554

Date of fiscal year end:  December 31

Date of reporting period:  June 30, 2019

Form N-CSR is to be used by management investment companies to file reports with the Commission not later than 10 days after the transmission to stockholders of any report that is required to be transmitted to stockholders under Rule 30e-1 under the Investment Company Act of 1940 (17 CFR 270.30e-1). The Commission may use the information provided on Form N-CSR in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-CSR, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-CSR unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. § 3507.


Item 1.

Reports to Stockholders.

The Report to Shareholders is attached herewith.


The Gabelli Healthcare & WellnessRx Trust

Semiannual Report — June 30, 2019

(Y)our Portfolio Management Team

 

LOGO   LOGO   LOGO
Mario J. Gabelli, CFA   Kevin V. Dreyer   Jeffrey J. Jonas, CFA
Chief Investment Officer   Co-Chief Investment Officer        Portfolio Manager
  BSE, University of Pennsylvania       BS, Boston College
  MBA, Columbia Business School  

To Our Shareholders,

For the six months ended June 30, 2019, the net asset value (NAV) total return of The Gabelli Healthcare & WellnessRx Trust (the Fund) was 13.1%, compared with a total return of 8.1% for the Standard & Poor’s (S&P) 500 Health Care Index. The total return for the Fund’s publicly traded shares was 16.9%. The Fund’s NAV per share was $12.10, while the price of the publicly traded shares closed at $10.53 on the New York Stock Exchange (NYSE). See page 2 for additional performance information.

Enclosed are the financial statements, including the schedule of investments, as of June 30, 2019.

 

 

 

Beginning on January 1, 2021, as permitted by regulations adopted by the Securities and Exchange Commission, paper copies of the Fund’s annual and semiannual shareholder reports will no longer be sent by mail, unless you specifically request paper copies of the reports. Instead, the reports will be made available on the Fund’s website (www.gabelli.com), and you will be notified by mail each time a report is posted and provided with a website link to access the report. If you already elected to receive shareholder reports electronically, you will not be affected by this change and you need not take any action. To elect to receive all future reports on paper free of charge, please contact your financial intermediary, or, if you invest directly with the Fund, you may call 800-422-3554 or send an email request to info@gabelli.com.


Comparative Results

 

Average Annual Returns through June 30, 2019 (a) (Unaudited)  
     Year to Date      1 Year     3 Year     5 Year     10 Year     Since
Inception
(06/28/07)
 

Gabelli Healthcare & WellnessRx Trust

             

NAV Total Return (b)

     13.11%        6.80     4.25     6.35     13.41     9.40%  

Investment Total Return (c)

     16.89           10.60       4.74       5.78       14.47       7.89     

S&P 500 Health Care Index

     8.07           12.99       10.82       10.61       15.52       10.44     

S&P 500 Index

     18.54           10.42       14.19       10.71       14.70       8.01     

S&P 500 Consumer Staples Index

     16.18           16.39       4.84       8.39       12.83       9.65     

50% S&P 500 Health Care Index and 50% S&P 500 Consumer Staples Index (The Blended Index)

     12.13           14.69       7.83       9.50       14.18       10.05     
  (a)

Returns represent past performance and do not guarantee future results. Investment returns and the principal value of an investment will fluctuate. The Fund’s use of leverage may magnify the volatility of net asset value changes versus funds that do not employ leverage. When shares are sold, they may be worth more or less than their original cost. Current performance may be lower or higher than the performance data presented. Visit www.gabelli.com for performance information as of the most recent month end. Performance returns for periods of less than one year are not annualized. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The S&P 500 Health Care Index is an unmanaged indicator of health care equipment and services, pharmaceuticals, biotechnology, and life sciences stock performance. The S&P 500 Index is an unmanaged indicator of stock market performance. The S&P 500 Consumer Staples Index is an unmanaged indicator of food and staples retailing, food, beverage and tobacco, and household and personal products stock performance. Dividends are considered reinvested. You cannot invest directly in an index.

 
  (b)

Total returns and average annual returns reflect changes in the NAV per share, reinvestment of distributions at NAV on the ex-dividend date, and adjustments for rights offerings and are net of expenses. Since inception return is based on an initial NAV of $8.00.

 
  (c)

Total returns and average annual returns reflect changes in closing market values on the NYSE, reinvestment of distributions, and adjustments for rights offerings. Since inception return is based on an initial offering price of $8.00.

 

 

2


Summary of Portfolio Holdings (Unaudited)

The following table presents portfolio holdings as a percent of total investments as of June 30, 2019:

The Gabelli Healthcare & WellnessRx Trust

 

Food

     22.6

Health Care Equipment and Supplies

     16.7

Pharmaceuticals

     16.0

Health Care Providers and Services

     15.9

Biotechnology

     8.2

Beverages

     5.3

U.S. Government Obligations

     4.3

Household and Personal Products

     3.9

Food and Staples Retailing

     3.3

Electronics

     2.0

Specialty Chemicals

     1.6

Hotels and Gaming

     0.2
  

 

 

 
     100.0
  

 

 

 
 

 

The Fund files a complete schedule of portfolio holdings with the Securities and Exchange Commission (the SEC) for the first and third quarters of each fiscal year on Form N-PORT. Shareholders may obtain this information at www.gabelli.com or by calling the Fund at 800-GABELLI (800-422-3554). The Fund’s Form N-PORT is available on the SEC’s website at www.sec.gov and may also be reviewed and copied at the SEC’s Public Reference Room in Washington, DC. Information on the operation of the Public Reference Room may be obtained by calling 800-SEC-0330.

Proxy Voting

The Fund files Form N-PX with its complete proxy voting record for the twelve months ended June 30, no later than August 31 of each year. A description of the Fund’s proxy voting policies, procedures, and how the Fund voted proxies relating to portfolio securities is available without charge, upon request, by (i) calling 800-GABELLI (800-422-3554); (ii) writing to The Gabelli Funds at One Corporate Center, Rye, NY 10580-1422; or (iii) visiting the SEC’s website at www.sec.gov.

Certifications

The Fund’s Chief Executive Officer has certified to the New York Stock Exchange (NYSE) that, as of June 11, 2019, she was not aware of any violation by the Fund of applicable NYSE corporate governance listing standards. The Fund reports to the SEC on Form N-CSR which contains certifications by the Fund’s principal executive officer and principal financial officer that relate to the Fund’s disclosure in such reports and that are required by Rule 30a-2(a) under the 1940 Act.

 

3


The Gabelli Healthcare & WellnessRx Trust

Schedule of Investments — June 30, 2019 (Unaudited)

 

 

 

Shares

       

Cost

   

Market

Value

 
 

COMMON STOCKS — 95.7%

 

 

Beverages — 5.3%

 

  60,000    

China Mengniu Dairy Co. Ltd.

  $ 134,296     $ 232,344  
  69,000    

Danone SA

    4,505,091       5,845,263  
  41,000    

ITO EN Ltd.

    971,431       1,909,011  
  40,000    

Keurig Dr Pepper Inc.

    906,420       1,156,000  
  30,000    

Massimo Zanetti Beverage Group SpA

    361,307       199,902  
  7,000    

Morinaga Milk Industry Co. Ltd.

    121,875       276,910  
  20,000    

PepsiCo Inc.

    1,352,672       2,622,600  
  30,000    

Suntory Beverage & Food Ltd.

    1,001,275       1,303,622  
  424,000    

Vitasoy International Holdings Ltd.

    253,570       2,038,122  
   

 

 

   

 

 

 
      9,607,937       15,583,774  
   

 

 

   

 

 

 
 

Biotechnology — 8.2%

 

  21,000    

Alexion Pharmaceuticals Inc.†

    2,351,892       2,750,580  
  50,000    

Array BioPharma Inc.†

    2,329,000       2,316,500  
  8,500    

Bio-Rad Laboratories Inc., Cl. A†

    2,401,630       2,657,015  
  25,000    

Celgene Corp.†

    2,185,856       2,311,000  
  17,500    

Charles River Laboratories International Inc.†

    1,718,125       2,483,250  
  16,000    

Clovis Oncology Inc.†

    325,982       237,920  
  2,000    

Idorsia Ltd.†

    20,590       45,687  
  3,800    

Illumina Inc.†

    202,951       1,398,970  
  6,500    

Invitae Corp.†

    57,709       152,750  
  25,000    

Ligand Pharmaceuticals Inc.†

    3,279,995       2,853,750  
  62,190    

NeoGenomics Inc.†

    908,228       1,364,449  
  1,200    

Regeneron Pharmaceuticals Inc.†

    420,992       375,600  
  44,000    

Spark Therapeutics Inc.†

    4,993,340       4,504,720  
  12,000    

Tetraphase Pharmaceuticals Inc.†

    47,033       5,764  
  1,600    

Waters Corp.†

    197,843       344,384  
   

 

 

   

 

 

 
      21,441,166       23,802,339  
   

 

 

   

 

 

 
 

Electronics — 2.0%

 

  20,000    

Thermo Fisher Scientific Inc.

    2,377,250       5,873,600  
   

 

 

   

 

 

 
 

Food — 22.6%

 

  15,000    

Calavo Growers Inc.

    498,575       1,451,100  
  35,000    

Campbell Soup Co.

    1,387,115       1,402,450  
  3,200    

Chr. Hansen Holding A/S

    180,647       300,493  
  190,000    

Conagra Brands Inc.

    5,553,070       5,038,800  
  67,500    

Flowers Foods Inc.

    657,458       1,570,725  
  64,000    

General Mills Inc.

    2,795,831       3,361,280  
  5,400    

John B Sanfilippo & Son Inc.

    201,924       430,326  
  68,800    

Kellogg Co.

    3,852,418       3,685,616  
  35,000    

Kerry Group plc, Cl. A

    1,331,659       4,178,843  
  120,000    

Kikkoman Corp.

    1,463,825       5,220,053  
  30,000    

Lamb Weston Holdings Inc.

    617,025       1,900,800  
  38,000    

Lifeway Foods Inc.†

    340,306       138,320  
  23,000    

Maple Leaf Foods Inc.

    410,536       503,715  

Shares

       

Cost

   

Market

Value

 
  15,000    

MEIJI Holdings Co. Ltd.

  $ 310,384     $ 1,071,279  
  110,000    

Mondelēz International Inc., Cl. A

    3,210,260       5,929,000  
  70,000    

Nestlé SA

    4,386,867       7,246,671  
  50,000    

Nomad Foods Ltd.†

    969,772       1,068,000  
  55,000    

Post Holdings Inc.†

    2,015,206       5,718,350  
  148,000    

The Hain Celestial Group Inc.†

    3,244,956       3,241,200  
  29,400    

The J.M. Smucker Co.

    1,878,207       3,386,586  
  110,000    

Tingyi (Cayman Islands) Holding Corp.

    176,608       183,622  
  75,000    

Unilever plc, ADR

    2,456,359       4,647,750  
  70,000    

Yakult Honsha Co. Ltd.

    2,252,034       4,122,803  
   

 

 

   

 

 

 
      40,191,042       65,797,782  
   

 

 

   

 

 

 
 

Food and Staples Retailing — 3.3%

 

  81,000    

CVS Health Corp.

    2,964,575       4,413,690  
  30,000    

Ingles Markets Inc., Cl. A

    454,430       933,900  
  50,000    

Sprouts Farmers Market Inc.†

    1,100,844       944,500  
  100,000    

The Kroger Co.

    1,307,173       2,171,000  
  10,000    

United Natural Foods Inc.†

    216,749       89,700  
  20,000    

Walgreens Boots Alliance Inc.

    1,281,136       1,093,400  
   

 

 

   

 

 

 
      7,324,907       9,646,190  
   

 

 

   

 

 

 
 

Health Care Equipment and Supplies — 16.7%

 

  60,000    

Baxter International Inc.

    2,699,996       4,914,000  
  12,000    

Becton, Dickinson and Co.

    2,662,815       3,024,120  
  32,000    

Boston Scientific Corp.†

    198,147       1,375,360  
  61,834    

Cardiovascular Systems Inc.†

    1,810,543       2,654,534  
  17,000    

Cutera Inc.†

    182,905       353,260  
  35,000    

DENTSPLY SIRONA Inc.

    1,420,490       2,042,600  
  50,795    

Electromed Inc.†

    274,294       276,833  
  30,000    

Gerresheimer AG

    1,443,645       2,208,817  
  20,000    

Globus Medical Inc., Cl. A†

    477,686       846,000  
  20,000    

Henry Schein Inc.†

    403,019       1,398,000  
  15,400    

ICU Medical Inc.†

    3,563,054       3,879,414  
  265,000    

InfuSystems Holdings Inc.†

    786,388       1,139,500  
  20,000    

Integer Holdings Corp.†

    428,850       1,678,400  
  40,000    

Medtronic plc

    3,063,278       3,895,600  
  40,000    

Nevro Corp.†

    1,998,358       2,593,200  
  10,000    

NuVasive Inc.†

    370,388       585,400  
  115,000    

Nuvectra Corp.†

    1,204,581       385,250  
  51,000    

Patterson Cos. Inc.

    1,506,859       1,167,900  
  14,485    

Semler Scientific Inc.†

    418,599       632,995  
  5,000    

Smith & Nephew plc, ADR

    168,590       217,700  
  50,000    

Stericycle Inc.†

    3,154,234       2,387,500  
  12,000    

Stryker Corp.

    678,145       2,466,960  
  30,000    

SurModics Inc.†

    1,025,145       1,295,100  
  8,000    

The Cooper Companies Inc.

    580,110       2,695,120  
  40,000    

Zimmer Biomet Holdings Inc.

    4,271,347       4,709,600  
   

 

 

   

 

 

 
      34,791,466       48,823,163  
   

 

 

   

 

 

 
 

Health Care Providers and Services — 15.9%

 

  55,000    

AmerisourceBergen Corp.

    3,442,893       4,689,300  
  20,000    

Anthem Inc.

    3,574,400       5,644,200  
 

 

See accompanying notes to financial statements.

 

4


The Gabelli Healthcare & WellnessRx Trust

Schedule of Investments (Continued) — June 30, 2019 (Unaudited)

 

 

Shares

       

Cost

   

Market

Value

 
 

COMMON STOCKS (Continued)

 

 

Health Care Providers and Services (Continued)

 

  40,000    

BioTelemetry Inc.†

  $ 1,422,405     $ 1,926,000  
  50,000    

Covetrus Inc.†

    1,287,854       1,223,000  
  60,000    

DaVita Inc.†

    3,637,833       3,375,600  
  362,000    

Evolent Health Inc., Cl. A†

    5,931,749       2,877,900  
  50,000    

HCA Healthcare Inc.

    3,492,952       6,758,500  
  27,200    

Laboratory Corp. of America Holdings†

    3,278,880       4,702,880  
  15,000    

McKesson Corp.

    1,044,224       2,015,850  
  47,574    

Orthofix Medical Inc.†

    1,436,128       2,515,713  
  80,000    

PetIQ Inc.†

    2,107,261       2,636,800  
  36,000    

Teladoc Health Inc.†

    1,745,650       2,390,760  
  101,417    

Tenet Healthcare Corp.†

    2,221,660       2,095,275  
  13,900    

UnitedHealth Group Inc.

    1,550,826       3,391,739  
   

 

 

   

 

 

 
      36,174,715       46,243,517  
   

 

 

   

 

 

 
 

Hotels and Gaming — 0.2%

 

  7,500    

Ryman Hospitality Properties Inc., REIT

    203,045       608,175  
   

 

 

   

 

 

 
 

Household and Personal Products — 3.9%

 

  50,000    

Church & Dwight Co. Inc.

    1,654,365       3,653,000  
  30,000    

Colgate-Palmolive Co.

    1,859,734       2,150,100  
  35,000    

Edgewell Personal Care Co.†

    2,289,230       943,250  
  30,000    

Energizer Holdings Inc.

    982,875       1,159,200  
  12,000    

The Estee Lauder Companies Inc., Cl. A

    804,725       2,197,320  
  13,000    

The Procter & Gamble Co.

    1,000,591       1,425,450  
   

 

 

   

 

 

 
      8,591,520       11,528,320  
   

 

 

   

 

 

 
 

Pharmaceuticals — 16.0%

 

  65,000    

Abbott Laboratories

    2,527,022       5,466,500  
  15,000    

Achaogen Inc.†

    6,945       283  
  37,500    

Allergan plc

    6,078,745       6,278,625  
  65,000    

Bausch Health Cos. Inc.†

    1,546,511       1,639,300  
  769,168    

BioScrip Inc.†

    1,539,660       1,999,837  
  44,000    

Bristol-Myers Squibb Co.

    1,567,758       1,995,400  
  37,000    

Cigna Corp.

    5,288,089       5,829,350  
  38,500    

Johnson & Johnson

    3,799,591       5,362,280  
  1,000    

Melinta Therapeutics Inc.†

    3,911       6,650  
  64,000    

Merck & Co. Inc.

    3,063,343       5,366,400  
  35,000    

Mylan NV†

    1,690,740       666,400  
  10,000    

Paratek Pharmaceuticals Inc.†

    74,914       39,900  
  60,000    

Perrigo Co. plc

    3,407,328       2,857,200  
  64,000    

Pfizer Inc.

    1,406,095       2,772,480  
  12,000    

Roche Holding AG, ADR

    250,095       421,200  
  151,020    

Takeda Pharmaceutical Co. Ltd., ADR

    2,920,727       2,673,054  
  30,000    

Zoetis Inc.

    1,313,659       3,404,700  
   

 

 

   

 

 

 
      36,485,133       46,779,559  
   

 

 

   

 

 

 

Shares

       

Cost

   

Market

Value

 
 

Specialty Chemicals — 1.6%

 

  31,273    

International Flavors & Fragrances Inc.

  $ 3,109,627     $ 4,537,400  
   

 

 

   

 

 

 
 

TOTAL COMMON STOCKS

    200,297,808       279,223,819  
   

 

 

   

 

 

 
 

PREFERRED STOCKS — 0.0%

 

 

Pharmaceuticals — 0.0%

 

  146    

BioScrip Inc., Zero
Coupon(a)

    13,852       14,243  
   

 

 

   

 

 

 
 

RIGHTS — 0.0%

 

 

Biotechnology — 0.0%

 

  6,907    

Tobira Therapeutics Inc.†(b)

    414       414  
   

 

 

   

 

 

 
 

Health Care Equipment and Supplies — 0.0%

 

  40,000    

American Medical Alert Corp., CPR†(b)

    0       400  
   

 

 

   

 

 

 
 

Pharmaceuticals — 0.0%

 

  3,500    

Ipsen SA/Clementia,
CVR†(b)

    4,725       4,725  
   

 

 

   

 

 

 
 

TOTAL RIGHTS

    5,139       5,539  
   

 

 

   

 

 

 
 

WARRANTS — 0.0%

   
 

Pharmaceuticals — 0.0%

 

  420    

BioScrip Inc., Cl. A, expire 07/27/25†

    384       148  
  420    

BioScrip Inc., Cl. B, expire 07/27/25†

    363       129  
   

 

 

   

 

 

 
 

TOTAL WARRANTS

    747       277  
   

 

 

   

 

 

 

Principal
Amount

                 
 

U.S. GOVERNMENT OBLIGATIONS — 4.3%

 

  $12,500,000    

U.S. Treasury Bills, 2.090% to 2.481%††, 07/25/19 to 09/19/19

    12,457,846       12,461,222  
   

 

 

   

 

 

 
  TOTAL INVESTMENTS — 100.0%   $ 212,775,392       291,705,100  
   

 

 

   
 

Other Assets and Liabilities (Net)

      (262,297
 

PREFERRED STOCK
(2,681,443 preferred shares outstanding)


 
    (67,036,075
     

 

 

 
 

NET ASSETS — COMMON STOCK
(18,543,423 common shares outstanding)


 
  $ 224,406,728  
     

 

 

 
 

NET ASSET VALUE PER COMMON SHARE
($224,406,728 ÷ 18,543,423 shares outstanding)


 
  $ 12.10  
     

 

 

 
 

 

See accompanying notes to financial statements.

 

5


The Gabelli Healthcare & WellnessRx Trust

Schedule of Investments (Continued) — June 30, 2019 (Unaudited)

 

 

 

(a)

Security is perpetual and has no stated maturity date.

(b)

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

Non-income producing security.

††

Represents annualized yields at dates of purchase.

ADR

American Depository Receipt

CPR

Contingent Payment Right

CVR

Contingent Value Right

REIT

Real Estate Investment Trust

Geographic Diversification   

% of Total

Investments

    

Market

Value

 

North America

     82.1      $ 239,541,153  

Europe

     11.4          33,133,127  

Japan

     5.7          16,576,732  

Asia/Pacific

     0.8          2,454,088  
  

 

 

      

 

 

 

Total Investments

     100.0      $ 291,705,100  
  

 

 

      

 

 

 
 

 

See accompanying notes to financial statements.

 

6


The Gabelli Healthcare & WellnessRx Trust

 

Statement of Assets and Liabilities

June 30, 2019 (Unaudited)

 

 

Assets:

  

Investments, at value (cost $212,775,392)

   $ 291,705,100  

Foreign currency, at value (cost $2,164)

     2,165  

Dividends receivable

     388,777  

Deferred offering expense

     109,878  

Prepaid expenses

     3,662  

Other receivable

     33,250  
  

 

 

 

Total Assets

     292,242,832  
  

 

 

 

Liabilities:

  

Payable to custodian

     63,145  

Distributions payable

     54,220  

Payable for Fund shares redeemed

     81,893  

Payable for investments purchased

     214,266  

Payable for investment advisory fees

     237,021  

Payable for payroll expenses

     37,732  

Payable for accounting fees

     7,500  

Other accrued expenses

     104,252  
  

 

 

 

Total Liabilities

     800,029  
  

 

 

 

Preferred Shares:

  

Series A Cumulative Preferred Shares (5.760%, $25 liquidation value, $0.001 par value, 1,200,000 shares authorized, issued, and outstanding)

     30,000,000  

Series B Cumulative Preferred Shares (5.875%, $25 liquidation value, $0.001 par value, 1,481,443 shares authorized, issued, and outstanding)

     37,036,075  
  

 

 

 

Total Preferred Shares

     67,036,075  
  

 

 

 

Net Assets Attributable to Common Shareholders

   $ 224,406,728  
  

 

 

 

Net Assets Attributable to Common Shareholders Consist of:

  

Paid-in capital

   $ 142,668,112  

Total distributable earnings

     81,738,616  
  

 

 

 

Net Assets

   $ 224,406,728  
  

 

 

 

Net Asset Value per Common Share:

  

($224,406,728 ÷ 18,543,423 shares outstanding at $0.001 par value; unlimited number of shares authorized)

   $ 12.10  
  

 

 

 

 

Statement of Operations

For the Six Months Ended June 30, 2019 (Unaudited)

 

 

Investment Income:

  

Dividends (net of foreign withholding taxes of $89,570)

   $ 1,897,790  

Interest

     186,892  
  

 

 

 

Total Investment Income

     2,084,682  
  

 

 

 

Expenses:

  

Investment advisory fees

     1,429,673  

Shareholder communications expenses

     91,540  

Payroll expenses

     51,702  

Shareholder services fees

     43,609  

Legal and audit fees

     38,011  

Trustees’ fees

     27,735  

Accounting fees

     22,500  

Custodian fees

     12,261  

Miscellaneous expenses

     40,809  
  

 

 

 

Total Expenses

     1,757,840  
  

 

 

 

Less:

  

Expenses paid indirectly by broker (See Note 3)

     (1,686
  

 

 

 

Net Expenses

     1,756,154  
  

 

 

 

Net Investment Income

     328,528  
  

 

 

 

Net Realized and Unrealized Gain/(Loss) on Investments and Foreign Currency:

  

Net realized gain on investments

     10,017,255  

Net realized loss on foreign currency transactions

     (109
  

 

 

 

Net realized gain on investments and foreign currency transactions

     10,017,146  
  

 

 

 

Net change in unrealized appreciation/depreciation:

  

on investments

     17,972,553  

on foreign currency translations

     1,882  
  

 

 

 

Net change in unrealized appreciation/ depreciation on investments and foreign currency translations

     17,974,435  
  

 

 

 

Net Realized and Unrealized Gain/(Loss) on Investments and Foreign Currency

     27,991,581  
  

 

 

 

Net Increase in Net Assets Resulting from Operations

     28,320,109  
  

 

 

 

Total Distributions to Preferred Shareholders

     (1,951,935
  

 

 

 

Net Increase in Net Assets Attributable to Common Shareholders Resulting from Operations

   $ 26,368,174  
  

 

 

 
 

 

See accompanying notes to financial statements.

 

7


The Gabelli Healthcare & WellnessRx Trust

Statement of Changes in Net Assets Attributable To Common Shareholders

 

 

 

     Six Months Ended
June 30, 2019
(Unaudited)
   Year Ended
December 31, 2018

Operations:

                 

Net investment income

     $ 328,528          $ 1,397,900    

Net realized gain on investments and foreign currency transactions

       10,017,146            13,351,930    

Net change in unrealized appreciation/depreciation on investments and foreign currency translations

       17,974,435            (17,028,973 )    
    

 

 

          

 

 

     

Net Increase/(Decrease) in Net Assets Resulting from Operations

       28,320,109            (2,279,143 )    
    

 

 

          

 

 

     

Distributions to Preferred Shareholders

       (1,951,935 )*            (3,903,869 )    
    

 

 

          

 

 

     

Net Increase/(Decrease) in Net Assets Attributable to Common Shareholders Resulting from Operations

       26,368,174            (6,183,012 )    
    

 

 

          

 

 

     

Distributions to Common Shareholders

       (5,198,232 )*            (10,103,985 )    
    

 

 

          

 

 

     

Fund Share Transactions:

                 

Net decrease from repurchase of common shares

       (1,376,366 )            (11,746,403 )    

Adjustment to offering costs for common shares

                  2,197    
    

 

 

          

 

 

     

Net Decrease in Net Assets from Fund Share Transactions

       (1,376,366 )            (11,744,206 )    
    

 

 

          

 

 

     

Net Increase/(Decrease) in Net Assets Attributable to Common Shareholders

       19,793,576            (28,031,203 )    
    

 

 

          

 

 

     

Net Assets Attributable to Common Shareholders:

                 

Beginning of year

       204,613,152            232,644,355    
    

 

 

          

 

 

     

End of period

     $ 224,406,728          $ 204,613,152    
    

 

 

          

 

 

     

 

*

Based on year to date book income. Amounts are subject to change and recharacterization at year end.

 

See accompanying notes to financial statements.

 

8


The Gabelli Healthcare & WellnessRx Trust

Financial Highlights

 

 

Selected data for a common share of beneficial interest outstanding throughout each period:

     Six Months Ended                                
     June 30, 2019     Year Ended December 31,  
     (Unaudited)     2018     2017     2016     2015     2014  

Operating Performance:

            

Net asset value, beginning of year

   $ 10.95     $ 11.74     $ 10.86     $ 11.79     $ 11.76     $ 11.33  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income/(loss)

     0.02       0.07       (0.01     (0.02     (0.03     0.01  

Net realized and unrealized gain/(loss) on investments, and foreign currency transactions

     1.51       (0.23     1.61       (0.21     0.75       2.04  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total from investment operations

     1.53       (0.16     1.60       (0.23     0.72       2.05  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Distributions to Preferred Shareholders:(a)

            

Net investment income

     (0.00 )*(b)      (0.02     (0.01                  

Net realized short term/long term gain

     (0.11 )*      (0.18     (0.19     (0.19     (0.19     (0.13
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total distributions to preferred shareholders

     (0.11     (0.20     (0.20     (0.19     (0.19     (0.13
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net Increase in Net Assets Attributable to Common Shareholders Resulting from Operations

     1.42       (0.36     1.40       (0.42     0.53       1.92  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Distributions to Common Shareholders:

            

Net investment income

     (0.01 )*      (0.05     (0.00 )(b)                   

Net realized short term/long term gain

     (0.27 )*      (0.47     (0.51     (0.52     (0.51     (0.62

Return of capital

                 (0.01                  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total distributions to common shareholders

     (0.28     (0.52     (0.52     (0.52     (0.51     (0.62
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Fund Share Transactions:

            

Increase in net asset value from repurchase of common shares

     0.01       0.09       0.00 (b)            0.01        

Decrease in net asset value from common shares issued in rights offering

                                   (0.77

Offering costs for preferred shares charged to paid-in capital

                                   (0.08

Offering costs and adjustment to offering costs for common shares charged to paid-in capital

           0.00 (b)                  (0.00 )(b)      (0.02

Increase in net asset value from offering of preferred shares

                       0.01              
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total Fund share transactions

     0.01       0.09       0.00 (b)      0.01       0.01       (0.87
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net Asset Value Attributable to Common Shareholders, End of Period

   $ 12.10     $ 10.95     $ 11.74     $ 10.86     $ 11.79     $ 11.76  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

NAV total return †

     13.11     (2.65 )%      13.02     (3.63 )%      4.55     16.98
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Market value, end of period

   $ 10.53     $ 9.25     $ 10.33     $ 9.43     $ 10.25     $ 10.42  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Investment total return ††

     16.89     (5.78 )%      15.17     (3.15 )%      3.14     10.39
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

See accompanying notes to financial statements.

 

9


The Gabelli Healthcare & WellnessRx Trust

Financial Highlights (Continued)

 

Selected data for a common share of beneficial interest outstanding throughout each period:

 

    Six Months Ended                                
    June 30, 2019     Year Ended December 31,  
    (Unaudited)     2018     2017     2016     2015     2014  

Ratios to Average Net Assets and Supplemental Data:

           

Net assets including liquidation value of preferred shares, end of period (in 000’s)

  $ 291,443     $ 271,649     $ 299,680     $ 282,611     $ 299,097     $ 299,595  

Net assets attributable to common shares, end of period (in 000’s)

  $ 224,407     $ 204,613     $ 232,644     $ 215,575     $ 234,097     $ 234,595  

Ratio of net investment income/(loss) to average net assets attributable to common shares before preferred share distributions

    0.30 %(c)      0.60     (0.07 )%      (0.20 )%      (0.22 )%      (0.27 )% 

Ratio of operating expenses to average net assets attributable to common shares (d)

    1.60 %(c)(e)      1.61 %(e)      1.65 %(e)      1.62 %(e)      1.60 %(e)      1.63

Portfolio turnover rate

    17.0     32.4     34.3     31.7     52.4     43.5

Cumulative Preferred Shares:

           

5.760% Series A Preferred

           

Liquidation value, end of period (in 000’s)

  $ 30,000     $ 30,000     $ 30,000     $ 30,000     $ 30,000     $ 30,000  

Total shares outstanding (in 000’s)

    1,200       1,200       1,200       1,200       1,200       1,200  

Liquidation preference per share

  $ 25.00     $ 25.00     $ 25.00     $ 25.00     $ 25.00     $ 25.00  

Average market value (f)

  $ 25.65     $ 25.43     $ 25.89     $ 26.12     $ 25.96     $ 25.85  

Asset coverage per share (g)

  $ 108.69     $ 101.31     $ 111.76     $ 105.40     $ 115.04     $ 115.23  

5.875% Series B Preferred

           

Liquidation value, end of period (in 000’s)

  $ 37,036     $ 37,036     $ 37,036     $ 37,036     $ 35,000     $ 35,000  

Total shares outstanding (in 000’s)

    1,481       1,481       1,481       1,481       1,400       1,400  

Liquidation preference per share

  $ 25.00     $ 25.00     $ 25.00     $ 25.00     $ 25.00     $ 25.00  

Average market value (f)

  $ 25.90     $ 25.83     $ 26.67     $ 26.76     $ 26.09     $ 25.37  

Asset coverage per share (g)

  $ 108.69     $ 101.31     $ 111.76     $ 105.40     $ 115.04     $ 115.23  

Asset Coverage(h)

    435     405     447     422     460     461

 

Based on net asset value per share at commencement of operations of $8.00 per share, adjusted for reinvestment of distributions at the net asset value per share on ex-dividend dates including the effect of shares issued pursuant to the rights offerings, assuming full subscription by shareholders. Total return for a period of less than one year is not annualized.

††

Based on market value per share at initial public offering of $8.00 per share, adjusted for reinvestment of distributions at prices determined under the Fund’s dividend reinvestment plan including the effect of shares issued pursuant to the rights offerings, assuming full subscription by shareholders. Total return for a period of less than one year is not annualized.

*

Based on year to date book income. Amounts are subject to change and recharacterization at year end.

(a)

Calculated based on average common shares outstanding on the record dates throughout the years.

(b)

Amount represents less than $0.005 per share.

(c)

Annualized.

(d)

Ratio of operating expenses to average net assets including liquidation value of preferred shares for the six months ended June 30, 2019 and years ended December 31, 2018, 2017, 2016, 2015, and 2014 would have been 1.23%, 1.25%, 1.27%, 1.26%, 1.26%, and 1.36%, respectively.

(e)

The Fund received credits from a designated broker who agreed to pay certain Fund operating expenses. Had such payments not been made, this expense ratio for the year ended December 31, 2015 would have been 1.27%. For the six months ended June 30, 2019 and the years ended December 31, 2018, 2017, and 2016, there was no impact on the expense ratios.

(f)

Based on weekly prices.

(g)

Asset coverage per share is calculated by combining all series of preferred shares.

(h)

Asset coverage is calculated by combining all series of preferred shares.

See accompanying notes to financial statements.

 

10


The Gabelli Healthcare & WellnessRx Trust

Notes to Financial Statements (Unaudited)

 

1. Organization. The Gabelli Healthcare & WellnessRx Trust (the Fund) currently operates as a diversified closed-end management investment company organized as a Delaware statutory trust on February 20, 2007 and registered under the Investment Company Act of 1940 as amended (the 1940 Act). Investment operations commenced on June 28, 2007.

The Fund’s investment objective is long term growth of capital. The Fund will invest at least 80% of its assets, under normal market conditions, in equity securities and income producing securities of domestic and foreign companies in the healthcare and wellness industries. As a result, the Fund may be more susceptible to economic, political, and regulatory developments in this particular sector of the market, positive or negative, and may experience increased volatility to the Fund’s NAV and a magnified effect in its total return.

2. Significant Accounting Policies. As an investment company, the Fund follows the investment company accounting and reporting guidance, which is part of U.S. generally accepted accounting principles (GAAP) that may require the use of management estimates and assumptions in the preparation of its financial statements. Actual results could differ from those estimates. The following is a summary of significant accounting policies followed by the Fund in the preparation of its financial statements.

New Accounting Pronouncements. To improve the effectiveness of fair value disclosure requirements, the Financial Accounting Standards Board recently issued Accounting Standard Update (ASU) 2018-13, Fair Value Measurement Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13), which adds, removes, and modifies certain aspects relating to fair value disclosure. ASU 2018-13 is effective for interim and annual reporting periods beginning after December 15, 2019; early adoption of the additions relating to ASU 2018-13 is not required, even if early adoption is elected for the removals under ASU 2018-13. Management has early adopted the removals set forth in ASU 2018-13 in these financial statements and has not early adopted the additions set forth in ASU 2018-13.

Security Valuation. Portfolio securities listed or traded on a nationally recognized securities exchange or traded in the U.S. over-the-counter market for which market quotations are readily available are valued at the last quoted sale price or a market’s official closing price as of the close of business on the day the securities are being valued. If there were no sales that day, the security is valued at the average of the closing bid and asked prices or, if there were no asked prices quoted on that day, then the security is valued at the closing bid price on that day. If no bid or asked prices are quoted on such day, the security is valued at the most recently available price or, if the Board of Trustees (the Board) so determines, by such other method as the Board shall determine in good faith to reflect its fair market value. Portfolio securities traded on more than one national securities exchange or market are valued according to the broadest and most representative market, as determined by Gabelli Funds, LLC (the Adviser).

Portfolio securities primarily traded on a foreign market are generally valued at the preceding closing values of such securities on the relevant market, but may be fair valued pursuant to procedures established by the Board if market conditions change significantly after the close of the foreign market, but prior to the close of business on the day the securities are being valued. Debt obligations for which market quotations are readily available are valued at the average of the latest bid and asked prices. If there were no asked prices quoted on such day, the security is valued using the closing bid price, unless the Board determines such amount does not reflect the securities’ fair value, in which case these securities will be fair valued as determined by the Board. Certain securities are valued principally using dealer quotations. Futures contracts are valued at the

 

11


The Gabelli Healthcare & WellnessRx Trust

Notes to Financial Statements (Unaudited) (Continued)

 

 

closing settlement price of the exchange or board of trade on which the applicable contract is traded. OTC futures and options on futures for which market quotations are readily available will be valued by quotations received from a pricing service or, if no quotations are available from a pricing service, by quotations obtained from one or more dealers in the instrument in question by the Adviser.

Securities and assets for which market quotations are not readily available are fair valued as determined by the Board. Fair valuation methodologies and procedures may include, but are not limited to: analysis and review of available financial and non-financial information about the company; comparisons with the valuation and changes in valuation of similar securities, including a comparison of foreign securities with the equivalent U.S. dollar value American Depository Receipts securities at the close of the U.S. exchange; and evaluation of any other information that could be indicative of the value of the security.

The inputs and valuation techniques used to measure fair value of the Fund’s investments are summarized into three levels as described in the hierarchy below:

 

   

Level 1 — quoted prices in active markets for identical securities;

   

Level 2 — other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.); and

   

Level 3 — significant unobservable inputs (including the Board’s determinations as to the fair value of investments).

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input both individually and in the aggregate that is significant to the fair value measurement. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The summary of the Fund’s investments in securities by inputs used to value the Fund’s investments as of June 30, 2019 is as follows:

 

     Valuation Inputs     
     Level 1
Quoted Prices
   Level 2 Other Significant
Observable Inputs
   Level 3 Significant
Unobservable Inputs
   Total Market Value
at 6/30/19

INVESTMENTS IN SECURITIES:

                   

ASSETS (Market Value):

                   

Common Stocks (a)

       $279,223,819                      $279,223,819

Preferred Stocks (a)

              $       14,243               14,243

Rights (a)

                     $5,539        5,539

Warrants (a)

              277               277

U.S. Government Obligations

              12,461,222               12,461,222

TOTAL INVESTMENTS IN SECURITIES – ASSETS

       $279,223,819        $12,475,742        $5,539        $291,705,100

 

(a)

Please refer to the Schedule of Investments for the industry classifications of these portfolio holdings.

During the six months ended June 30, 2019 the Fund did not have transfers into or out of Level 3.

Additional Information to Evaluate Qualitative Information.

General. The Fund uses recognized industry pricing services – approved by the Board and unaffiliated with the Adviser– to value most of its securities, and uses broker quotes provided by market makers of securities not valued by these and other recognized pricing sources. Several different pricing feeds are received to value domestic equity securities, international equity securities, preferred equity securities, and fixed income securities.

 

12


The Gabelli Healthcare & WellnessRx Trust

Notes to Financial Statements (Unaudited) (Continued)

 

 

The data within these feeds are ultimately sourced from major stock exchanges and trading systems where these securities trade. The prices supplied by external sources are checked by obtaining quotations or actual transaction prices from market participants. If a price obtained from the pricing source is deemed unreliable, prices will be sought from another pricing service or from a broker/dealer that trades that security or similar securities.

Fair Valuation. Fair valued securities may be common or preferred equities, warrants, options, rights, or fixed income obligations. Where appropriate, Level 3 securities are those for which market quotations are not available, such as securities not traded for several days, or for which current bids are not available, or which are restricted as to transfer. When fair valuing a security, factors to consider include recent prices of comparable securities that are publicly traded, reliable prices of securities not publicly traded, the use of valuation models, current analyst reports, valuing the income or cash flow of the issuer, or cost if the preceding factors do not apply. A significant change in the unobservable inputs could result in a lower or higher value in Level 3 securities. The circumstances of Level 3 securities are frequently monitored to determine if fair valuation measures continue to apply.

The Adviser reports quarterly to the Board the results of the application of fair valuation policies and procedures. These may include backtesting the prices realized in subsequent trades of these fair valued securities to fair values previously recognized.

Foreign Currency Translations. The books and records of the Fund are maintained in U.S. dollars. Foreign currencies, investments, and other assets and liabilities are translated into U.S. dollars at current exchange rates. Purchases and sales of investment securities, income, and expenses are translated at the exchange rate prevailing on the respective dates of such transactions. Unrealized gains and losses that result from changes in foreign exchange rates and/or changes in market prices of securities have been included in unrealized appreciation/depreciation on investments and foreign currency translations. Net realized foreign currency gains and losses resulting from changes in exchange rates include foreign currency gains and losses between trade date and settlement date on investment securities transactions, foreign currency transactions, and the difference between the amounts of interest and dividends recorded on the books of the Fund and the amounts actually received. The portion of foreign currency gains and losses related to fluctuation in exchange rates between the initial purchase trade date and subsequent sale trade date is included in realized gain/(loss) on investments.

Foreign Securities. The Fund may directly purchase securities of foreign issuers. Investing in securities of foreign issuers involves special risks not typically associated with investing in securities of U.S. issuers. The risks include possible revaluation of currencies, the inability to repatriate funds, less complete financial information about companies, and possible future adverse political and economic developments. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than securities of comparable U.S. issuers.

Foreign Taxes. The Fund may be subject to foreign taxes on income, gains on investments, or currency repatriation, a portion of which may be recoverable. The Fund will accrue such taxes and recoveries as applicable, based upon its current interpretation of tax rules and regulations that exist in the markets in which it invests.

Securities Transactions and Investment Income. Securities transactions are accounted for on the trade date with realized gain/(loss) on investments determined by using the identified cost method. Interest income (including

 

13


The Gabelli Healthcare & WellnessRx Trust

Notes to Financial Statements (Unaudited) (Continued)

 

 

amortization of premium and accretion of discount) is recorded on an accrual basis. Premiums and discounts on debt securities are amortized using the effective yield to maturity method. Dividend income is recorded on the ex-dividend date, except for certain dividends from foreign securities that are recorded as soon after the ex-dividend date as the Fund becomes aware of such dividends.

Custodian Fee Credits and Interest Expense. When cash balances are maintained in the custody account, the Fund receives credits which are used to offset custodian fees. The gross expenses paid under the custody arrangement are included in custodian fees in the Statement of Operations with the corresponding expense offset, if any, shown as “Custodian fee credits.” When cash balances are overdrawn, the Fund is charged an overdraft fee equal to 110% of the 90 day U.S. Treasury Bill rate on outstanding balances. This amount, if any, would be included in the Statement of Operations.

Distributions to Shareholders. Distributions to common shareholders are recorded on the ex-dividend date. Distributions to shareholders are based on income and capital gains as determined in accordance with federal income tax regulations, which may differ from income and capital gains as determined under GAAP. These differences are primarily due to differing treatments of income and gains on various investment securities and foreign currency transactions held by the Fund, timing differences, and differing characterizations of distributions made by the Fund. Distributions from net investment income for federal income tax purposes include net realized gains on foreign currency transactions. These book/tax differences are either temporary or permanent in nature. To the extent these differences are permanent, adjustments are made to the appropriate capital accounts in the period when the differences arise. These reclassifications have no impact on the NAV of the Fund.

Distributions to shareholders of the Fund’s 5.76% Series A Cumulative Preferred Shares (Series A Preferred) and 5.875% Series B Cumulative Preferred Shares (Series B Preferred) are recorded on a daily basis and are determined as described in Note 5.

The Fund declares and pays quarterly distributions from net investment income, capital gains, and paid-in capital. The actual source of the distribution is determined after the end of the year. Distributions during the year may be made in excess of required distributions. To the extent such distributions are made from current earnings and profits, they are considered ordinary income or long term capital gains. The Fund’s current distribution policy may restrict the Fund’s ability to pass through to shareholders all of its net realized long term capital gains as a Capital Gain Dividend and may cause such gains to be treated as ordinary income, subject to the maximum federal income tax rate. Distributions sourced from paid-in capital should not be considered as dividend yield or the total return from an investment in the Fund. The Board will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s NAV and the financial market environment. The Fund’s distribution policy is subject to modification by the Board at any time.

 

14


The Gabelli Healthcare & WellnessRx Trust

Notes to Financial Statements (Unaudited) (Continued)

 

 

The tax character of distributions paid during the year ended December 31, 2018 was as follows:

 

    

Common

    

Preferred

 

Distributions paid from:

     

Ordinary income (inclusive of short term capital gains)

   $ 5,550,538      $ 2,144,557  

Net long term capital gains

     4,553,447        1,759,312  
  

 

 

    

 

 

 

Total distributions paid

   $ 10,103,985      $ 3,903,869  
  

 

 

    

 

 

 

Provision for Income Taxes. The Fund intends to continue to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code of 1986, as amended (the Code). It is the policy of the Fund to comply with the requirements of the Code applicable to regulated investment companies and to distribute substantially all of its net investment company taxable income and net capital gains. Therefore, no provision for federal income taxes is required.

The following summarizes the tax cost of investments and the related net unrealized appreciation at June 30, 2019:

 

     Cost    Gross
Unrealized
Appreciation
   Gross
Unrealized
Depreciation
  Net Unrealized
Appreciation

Investments

   $213,159,489    $90,193,756    $(11,648,145)   $78,545,611

The Fund is required to evaluate tax positions taken or expected to be taken in the course of preparing the Fund’s tax returns to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Income tax and related interest and penalties would be recognized by the Fund as tax expense in the Statement of Operations if the tax positions were deemed not to meet the more-likely-than-not threshold. During the six months ended June 30, 2019, the Fund did not incur any income tax, interest, or penalties. As of June 30, 2019, the Adviser has reviewed all open tax years and concluded that there was no impact to the Fund’s net assets or results of operations. The Fund’s federal and state tax returns for the prior three fiscal years remain open, subject to examination. On an ongoing basis, the Adviser will monitor the Fund’s tax positions to determine if adjustments to this conclusion are necessary.

3. Investment Advisory Agreement and Other Transactions. The Fund has entered into an investment advisory agreement (the Advisory Agreement) with the Adviser which provides that the Fund will pay the Adviser a fee, computed weekly and paid monthly, equal on an annual basis to 1.00% of the value of the Fund’s average weekly net assets including the liquidation value of preferred shares. In accordance with the Advisory Agreement, the Adviser provides a continuous investment program for the Fund’s portfolio and oversees the administration of all aspects of the Fund’s business and affairs.

During the six months ended June 30, 2019, the Fund paid $42,273 in brokerage commissions on security trades to G.research, LLC, an affiliate of the Adviser.

During the six months ended June 30, 2019, the Fund received credits from a designated broker who agreed to pay certain Fund operating expenses. The amount of such expenses paid through this directed brokerage arrangement during this period was $1,686.

The cost of calculating the Fund’s NAV per share is a Fund expense pursuant to the Advisory Agreement. Under the sub-administration agreement with Bank of New York Mellon, the fees paid include the cost of calculating

 

15


The Gabelli Healthcare & WellnessRx Trust

Notes to Financial Statements (Unaudited) (Continued)

 

 

the Fund’s NAV. The Fund reimburses the Adviser for this service. During the six months ended June 30, 2019, the Fund accrued $22,500 in accounting fees in the Statement of Operations.

As per the approval of the Board, the Fund compensates officers of the Fund, who are employed by the Fund and are not employed by the Adviser (although the officers may receive incentive based variable compensation from affiliates of the Adviser). During the six months ended June 30, 2019, the Fund accrued $51,702 in payroll expenses in the Statement of Operations.

The Fund pays each Trustee who is not considered an affiliated person an annual retainer of $3,000 plus $1,000 for each Board meeting attended. Each Trustee is reimbursed by the Fund for any out of pocket expenses incurred in attending meetings. All Board committee members receive $500 per meeting attended. In addition, the Audit Committee Chairman receives an annual fee of $3,000, the Nominating Committee Chairman receives an annual fee of $2,000, and the Lead Trustee receives an annual fee of $1,000. A Trustee may receive a single meeting fee, allocated among the participating funds, for participation in certain meetings held on behalf of multiple funds. Trustees who are directors or employees of the Adviser or an affiliated company receive no compensation or expense reimbursement from the Fund.

4. Portfolio Securities. Purchases and sales of securities during the six months ended June 30, 2019, other than short term securities and U.S. Government obligations, aggregated $46,365,958 and $52,286,880, respectively.

5. Capital. The Fund is authorized to issue an unlimited number of shares of beneficial interest (par value $0.001). The Board has authorized the repurchase of its shares on the open market when the shares are trading on the NYSE at a discount of 10% or more (or such other percentage as the Board may determine from time to time) from the NAV of the shares. During the six months ended June 30, 2019, the Fund repurchased and retired 134,355 common shares in the open market at an investment of $1,376,366 and an average discount of approximately 14.26% from its NAV. During the year ended December 31, 2018, the Fund repurchased and retired 1,130,986 common shares in the open market at an investment of $11,746,403 and an average discount of approximately 14.70% from its NAV.

Transactions in shares of beneficial interest were as follows:

 

     Six Months Ended          Year Ended  
    

June 30, 2019

        

December 31, 2018

 
    

Shares

       

Amount

        

Shares

      

Amount

 

Net decrease from repurchase of common shares

   (134,355)       $ (1,376,366      (1,130,986)      $ (11,746,403

The Fund has an effective shelf registration authorizing the offering of an additional $200 million of common or preferred shares.

The Fund’s Declaration of Trust, as amended, authorizes the issuance of an unlimited number of shares of $0.001 par value Preferred Shares. The Preferred Shares are senior to the common shares and result in the financial leveraging of the common shares. Such leveraging tends to magnify both the risks and opportunities to common shareholders. Dividends on Preferred Shares are cumulative. The Fund is required by the 1940 Act and by the Statement of Preferences to meet certain asset coverage tests with respect to the Preferred Shares. If the Fund fails to meet these requirements and does not correct such failure, the Fund may be required to redeem, in part or in full, the Preferred Shares at redemption prices of $25 per share plus an amount equal

 

16


The Gabelli Healthcare & WellnessRx Trust

Notes to Financial Statements (Unaudited) (Continued)

 

 

to the accumulated and unpaid dividends whether or not declared on such shares in order to meet these requirements. Additionally, failure to meet the foregoing asset coverage requirements could restrict the Fund’s ability to pay dividends to common shareholders and could lead to sales of portfolio securities at inopportune times. The income received on the Fund’s assets may vary in a manner unrelated to the fixed rates, which could have either a beneficial or detrimental impact on net investment income and gains available to common shareholders.

For the Series A Preferred at any time and for the Series B Preferred commencing September 24, 2019 and at any time thereafter, the Fund, at its option, may redeem the Series A Preferred or Series B Preferred at their redemption prices per share plus an amount equal to any accumulated and unpaid dividends whether or not declared on such shares. The Board has authorized the repurchase of the Series A Preferred and Series B Preferred in the open market at prices less than the $25 liquidation values per share. During the six months ended June 30, 2019 and the year ended December 31, 2018, the Fund did not repurchase any of the Series A Preferred or Series B Preferred.

The following table summarizes the Preferred Share information:

 

Series    Issue Date    Authorized      Number of Shares
Outstanding at
06/30/19
     Net
Proceeds
     2019 Dividend
Rate Range
   Dividend
Rate at
06/30/19
  Accrued
Dividends at
06/30/19
 

A 5.760%

   August 20, 2010      1,200,000        1,200,000                $28,725,173      Fixed Rate    5.760%     $24,000  

B 5.875%

   September 24, 2014      1,400,000        1,400,000                33,564,647      Fixed Rate    5.875%     28,709  

B 5.875%

   Various dates in 2016      81,443        81,443                2,192,721      Fixed Rate    5.875%     1,511  

The holders of Preferred Shares generally are entitled to one vote per share held on each matter submitted to a vote of shareholders of the Fund and will vote together with holders of common stock as a single class. The holders of Preferred Shares voting together as a single class also have the right currently to elect two Trustees and under certain circumstances are entitled to elect a majority of the Board. In addition, the affirmative vote of a majority of the votes entitled to be cast by holders of all outstanding shares of the Preferred Shares, voting as a single class, will be required to approve any plan of reorganization adversely affecting the Preferred Shares, and the approval of two-thirds of each class, voting separately, of the Fund’s outstanding voting stock must approve the conversion of the Fund from a closed-end to an open-end investment company. The approval of a majority (as defined in the 1940 Act) of the outstanding Preferred Shares and a majority (as defined in the 1940 Act) of the Fund’s outstanding voting securities are required to approve certain other actions, including changes in the Fund’s investment objectives or fundamental investment policies.

6. Industry Concentration. Because the Fund primarily invests in common stocks and other securities of foreign and domestic companies in the health care, pharmaceuticals, and food and beverage industries, its portfolio may be subject to greater risk and market fluctuations than a portfolio of securities representing a broad range of investments.

7. Indemnifications. The Fund enters into contracts that contain a variety of indemnifications. The Fund’s maximum exposure under these arrangements is unknown. However, the Fund has not had prior claims or losses pursuant to these contracts. Management has reviewed the Fund’s existing contracts and expects the risk of loss to be remote.

 

17


The Gabelli Healthcare & WellnessRx Trust

Notes to Financial Statements (Unaudited) (Continued)

 

 

8. Subsequent Events. Management has evaluated the impact of all subsequent events of the Fund and has determined that there were no subsequent events requiring recognition or disclosure in the financial statements.

Shareholder Meeting – May 13, 2019 – Final Results

The Fund’s Annual Meeting of Shareholders was held on May 13, 2019, in Greenwich, Connecticut. At that meeting, common and preferred shareholders, voting together as a single class, re-elected Jeffrey J. Jonas and Kuni Nakamura as Trustees of the Fund, with 18,482,440 votes and 17,296,029 votes cast in favor of these Trustees, and 513,248 votes and 1,699,658 votes withheld for these Trustees, respectively.

In addition, preferred shareholders, voting as a separate class, re-elected James P. Conn as a Trustee of the Fund, with 2,403,399 votes cast in favor of this Trustee and 91,923 votes withheld for this Trustee.

Mario J. Gabelli, Vincent D. Enright, Robert C. Kolodny, Anthonie C. van Ekris, and Salvatore J. Zizza continue to serve in their capacities as Trustees of the Fund.

We thank you for your participation and appreciate your continued support.

 

18


The Gabelli Healthcare & WellnessRx Trust

Board Consideration and Re-Approval of Investment Advisory Agreement (Unaudited)

Section 15(c) of the Investment Company Act of 1940, as amended (the 1940 Act), contemplates that the Board of Trustees (the Board) of The Gabelli Healthcare & WellnessRx Trust (the Fund), including a majority of the Trustees who have no direct or indirect interest in the Investment Advisory Agreement (the Advisory Agreement) and are not “interested persons” of the Fund, as defined in the 1940 Act (the Independent Board Members), are required to review and approve the terms of the Fund’s proposed Advisory Agreement. In this regard, the Board reviewed and approved, during the most recent six month period covered by this report, the Advisory Agreement with Gabelli Funds, LLC (the Adviser) for the Fund.

More specifically, at a meeting held on February 20, 2019, the Board, including the Independent Board Members, considered the factors and reached the conclusions described below relating to the selection of the Adviser and the approval of the Advisory Agreement.

Nature, Extent, and Quality of Services.

The Independent Board Members considered information regarding the portfolio managers, the depth of the analyst pool available to the Adviser and the portfolio managers, the scope of administrative, shareholder and other services supervised or provided by the Adviser and the absence of significant service problems reported to the Board. The Independent Board Members noted the experience, length of service, and reputation of the portfolio managers.

Investment Performance of the Fund and Adviser.

The Independent Board Members considered one year, three year, five year, and ten year investment performance for the Fund as compared to relevant sector equity indices and the performance of other sector equity closed-end and open-end funds prepared by the Adviser, including other funds focused on healthcare or biotechnology. The Independent Board Members noted that the Fund’s NAV performance was below the median of funds in its Adviser peer group for the prior one, three, five, and ten year periods, although the Fund’s performance during the ten year period was relatively in line with the Broadridge peer group. The Independent Board Members also recognized that the performance of many of the funds in the Broadridge peer group is not necessarily a good comparison for the Fund because of the Fund’s unique investment strategy compared to the investment strategies of many funds in the peer group. The Independent Board Members also noted that the NAV of the Fund had (i) underperformed the S&P 500 Health Care Index over the one year, three year, five year, and ten year periods, (ii) outperformed the S&P 500 Consumer Staples Index over the one and ten year periods and underperformed the S&P 500 Consumer Staples Index over the three year and five year periods, and (iii) underperformed an index comprised of 50% S&P 500 Health Care Index and 50% S&P 500 Consumer Staples Index over the one year, three year, five year, and ten year periods. As was the case for the peer comparisons, the Independent Board Members recognized that none of these indices is a good comparison for the Fund, since certain healthcare and consumer staples companies included in the indices vary from the companies in which the Fund is permitted to invest under its investment objective, policies, and restrictions (for example, consumer staples companies that are inconsistent with the Fund’s wellness mandate). In addition, the indices include growth companies that may not be consistent with the Adviser’s value-oriented investment strategy. The Independent Board Members therefore recognized the more limited usefulness of the Broadridge peer group comparison and the index comparisons, concluding that the Adviser was delivering satisfactory performance results consistent with the investment strategy being pursued by the Fund and disclosed to investors.

Costs of Services and Profits Realized by the Adviser.

(a) Costs of Services to Fund: Fees and Expenses. The Independent Board Members considered the Fund’s

 

19


The Gabelli Healthcare & WellnessRx Trust

Board Consideration and Re-Approval of Investment Advisory Agreement (Unaudited) (Continued)

 

management fee rate and expense ratio relative to industry averages for the Fund’s Broadridge peer group category and the advisory fees charged by the Adviser and its affiliates to other fund and non-fund clients. The Independent Board Members noted that the mix of services under the Agreement are much more extensive than those under the advisory agreements for non-fund clients. The Independent Board Members noted that the investment advisory fee (as a percentage of assets attributable to common shares), management fee (as a percentage of total managed assets), other non-management expenses and total expense ratio paid by the Fund are higher than the median and average for its Broadridge peer group. They were advised that the above average other non-management expenses and total expense ratio related in part to the large number of shareholder accounts and related transfer agency costs and the costs of leverage. They concluded that the management fee is acceptable based upon the qualifications, experience and reputation of the Adviser and the other factors considered.

(b) Profitability and Costs of Services to Adviser. The Independent Board Members considered the Adviser’s overall profitability and costs. The Independent Board Members referred to the Board Materials for the pro forma income statements for the Adviser and the Fund for the period ended December 31, 2018. They noted how the pro forma income statements for the Fund illustrated how the Adviser’s profitability would be affected as the Fund asset levels change. The Independent Board Members also considered whether the amount of profit is a fair entrepreneurial profit for the management of the Fund, and noted that the Adviser has continued to increase its resources devoted to Fund matters, including portfolio management resources, in response to, among other things, recently enacted regulatory requirements and new or enhanced Fund policies and procedures. The Independent Board Members concluded that the profitability to the Adviser of managing the Fund was not excessive.

Extent of Economies of Scale as Fund Grows.

The Independent Board Members considered whether there have been economies of scale with respect to the management of the Fund and whether the Fund has appropriately benefited from any economies of scale. The Independent Board Members noted that, although the ability of the Fund to realize economies of scale through growth is more limited than for an open-end fund, economies of scale may develop for certain funds as their assets increase and their fund-level expenses decline as a percentage of assets, but that fund-level economies of scale may not necessarily result in Adviser-level economies of scale. The Board Members were advised that economies of scale in the form of lower expenses are not likely to be realized until the Fund was of a larger size. Nonetheless, the Fund benefits from investments the Adviser has made in enhanced administrative, portfolio management, operational and other resources.

Whether Fee Levels Reflect Economies of Scale.

The Independent Board Members noted that the management fee rate for the period does not take into account any potential sharing of economies of scale through breakpoints.

Other Relevant Considerations.

(a) Adviser Personnel and Methods. The Independent Board Members considered the size, education and experience of the Adviser’s staff, the Adviser’s fundamental research capabilities and the Adviser’s approach to recruiting, training and retaining portfolio managers and other research and management personnel, and concluded that in each of these areas the Adviser was structured in such a way to support the high level of services being provided to the Fund.

 

20


The Gabelli Healthcare & WellnessRx Trust

Board Consideration and Re-Approval of Investment Advisory Agreement (Unaudited) (Continued)

 

(b) Other Benefits to the Adviser. The Independent Board Members also considered the character and amount of other incidental benefits received by the Adviser and its affiliates from its association with the Fund. The Independent Board Members considered the brokerage commissions paid to an affiliate of the Adviser. The Independent Board Members concluded that potential fall-out benefits that the Adviser and its affiliates may receive, such as brokerage commissions paid to an affiliated broker, greater name recognition or increased ability to obtain research services, appear to be reasonable, and may in some cases benefit the Fund.

Conclusions.

In considering the Agreement, the Independent Board Members did not identify any factor as all-important or all-controlling, and instead considered these factors collectively in light of the Fund’s surrounding circumstances. The Independent Board Members concluded that the Fund enjoyed highly experienced portfolio management services and good ancillary services. They were aware that the NAV performance record had been below the median during the one, three, five, and ten year reporting periods ended December 31, 2018 in comparison with peers but recognized that many of the peers were not good comparisons for the Fund because of its unique investment strategy. Similarly, index comparisons were not considered to be very meaningful for comparison purposes. As a part of its decision-making process the Independent Board Members understood that shareholders invested in the Fund with full disclosure that the Adviser managed the Fund and of the Fund’s investment management fee schedule. Given this, the Independent Board Members received regular reports on the Adviser’s management of the Fund in a manner consistent with its investment objectives and policies as disclosed to shareholders. In addition, the Independent Board Members believe that a long-term relationship with a capable, conscientious adviser is in the best interests of the Fund. On the basis of the foregoing and without assigning particular weight to any single conclusion, the Independent Board Members determined to recommend continuation of the Advisory Agreement to the full Board.

Based on a consideration of all these factors in their totality, the Board Members, including all of the Independent Board Members, determined that the Fund’s advisory fee was fair and reasonable with respect to the nature and quality of services provided and in light of the other factors described above that the Board deemed relevant. Accordingly, the Board Members determined to approve the continuation of the Fund’s Advisory Agreement. The Board Members based their decision on evaluations of all these factors as a whole and did not consider any one factor as all-important or controlling.

 

21


AUTOMATIC DIVIDEND REINVESTMENT

AND VOLUNTARY CASH PURCHASE PLANS

Enrollmentin the Plan

It is the policy of The Gabelli Healthcare & WellnessRx Trust to automatically reinvest dividends payable to common shareholders. As a “registered” shareholder, you automatically become a participant in the Fund’s Automatic Dividend Reinvestment Plan (the “Plan”). The Plan authorizes the Fund to credit shares of common stock to participants upon an income dividend or a capital gains distribution regardless of whether the shares are trading at a discount or a premium to net asset value. All distributions to shareholders whose shares are registered in their own names will be automatically reinvested pursuant to the Plan in additional shares of the Fund. Plan participants may send their stock certificates to Computershare Trust Company, N.A. (“Computershare”) to be held in their dividend reinvestment account. Registered shareholders wishing to receive their distribution in cash must submit this request in writing to:

The Gabelli Healthcare & WellnessRx Trust

c/o Computershare

P.O. Box 505000

Louisville, KY 40233

Shareholders requesting this cash election must include the shareholder’s name and address as they appear on the share certificate. Shareholders with additional questions regarding the Plan or requesting a copy of the terms of the Plan may contact Computershare at (800) 336-6983.

If your shares are held in the name of a broker, bank, or nominee, you should contact such institution. If such institution is not participating in the Plan, your account will be credited with a cash dividend. In order to participate in the Plan through such institution, it may be necessary for you to have your shares taken out of “street name” and re-registered in your own name. Once registered in your own name, your dividends will be automatically reinvested. Certain brokers participate in the Plan. Shareholders holding shares in “street name” at participating institutions will have dividends automatically reinvested. Shareholders wishing a cash dividend at such institution must contact their broker to make this change.

The number of shares of common stock distributed to participants in the Plan in lieu of cash dividends is determined in the following manner. Under the Plan, whenever the market price of the Fund’s common stock is equal to or exceeds net asset value at the time shares are valued for purposes of determining the number of shares equivalent to the cash dividends or capital gains distribution, participants are issued shares of common stock valued at the greater of (i) the net asset value as most recently determined or (ii) 95% of the then current market price of the Fund’s common stock. The valuation date is the dividend or distribution payment date or, if that date is not a New York Stock Exchange (“NYSE”) trading day, the next trading day. If the net asset value of the common stock at the time of valuation exceeds the market price of the common stock, participants will receive shares from the Fund valued at market price. If the Fund should declare a dividend or capital gains distribution payable only in cash, Computershare will buy common stock in the open market, or on the NYSE or elsewhere, for the participants’ accounts, except that Computershare will endeavor to terminate purchases in the open market and cause the Fund to issue shares at net asset value if, following the commencement of such purchases, the market value of the common stock exceeds the then current net asset value.

The automatic reinvestment of dividends and capital gains distributions will not relieve participants of any income tax which may be payable on such distributions. A participant in the Plan will be treated for federal income tax purposes as having received, on a dividend payment date, a dividend or distribution in an amount equal to the cash the participant could have received instead of shares.

Voluntary Cash Purchase Plan

The Voluntary Cash Purchase Plan is yet another vehicle for our shareholders to increase their investment in the Fund. In order to participate in the Voluntary Cash Purchase Plan, shareholders must have their shares registered in their own name.

Participants in the Voluntary Cash Purchase Plan have the option of making additional cash payments to Computershare for investments in the Fund’s shares at the then current market price. Shareholders may send an amount from $250 to $10,000. Computershare will use these funds to purchase shares in the open market on or about the 1st and 15th of each month. Computershare will charge each shareholder who participates $0.75, plus a pro rata share of the brokerage commissions. Brokerage charges for such purchases are expected to be less than the usual brokerage charge for such transactions. It is suggested that any voluntary cash payments be sent to Computershare, P.O. Box 505000, Louisville, KY 40233 such that Computershare receives such payments approximately 10 days before the 1st and 15th of the month. Funds not received at least five days before the investment date shall be held for investment until the next purchase date. A payment may be withdrawn without charge if notice is received by Computershare at least 48 hours before such payment is to be invested.

Shareholders wishing to liquidate shares held at Computershare must do so in writing or by telephone. Please submit your request to the above mentioned address or telephone number. Include in your request your name, address, and account number. The cost to liquidate shares is $2.50 per transaction as well as the brokerage commission incurred. Brokerage charges are expected to be less than the usual brokerage charge for such transactions.

For more information regarding the Dividend Reinvestment Plan and Voluntary Cash Purchase Plan, brochures are available by calling (914) 921-5070 or by writing directly to the Fund.

The Fund reserves the right to amend or terminate the Plan as applied to any voluntary cash payments made and any dividend or distribution paid subsequent to written notice of the change sent to the members of the Plan at least 90 days before the record date for such dividend or distribution. The Plan also may be amended or terminated by Computershare on at least 90 days written notice to participants in the Plan.

 

22


THE GABELLI HEALTHCARE & WELLNESSRx TRUST

One Corporate Center

Rye, NY 10580-1422

Portfolio Management Team Biographies

Mario J. Gabelli, CFA, is Chairman, Chief Executive Officer, and Chief Investment Officer - Value Portfolios of GAMCO Investors, Inc. that he founded in 1977, and Chief Investment Officer - Value Portfolios of Gabelli Funds, LLC and GAMCO Asset Management Inc. He is also Executive Chairman of Associated Capital Group, Inc. Mr. Gabelli is a summa cum laude graduate of Fordham University and holds an MBA degree from Columbia Business School and Honorary Doctorates from Fordham University and Roger Williams University.

Kevin V. Dreyer joined Gabelli in 2005 as a research analyst covering companies within the consumer sector. Currently he is a Managing Director and Co-Chief Investment Officer for GAMCO Investors, Inc.’s Value team. In addition, he serves as a portfolio manager of Gabelli Funds, LLC and manages several funds within the Gabelli/GAMCO Fund Complex. Mr. Dreyer received a BSE from the University of Pennsylvania and an MBA degree from Columbia Business School.

Jeffrey J. Jonas, CFA, joined Gabelli in 2003 as a research analyst focusing on companies across the healthcare industry. In 2006, he began serving as a portfolio manager of Gabelli Funds, LLC and manages several funds within the Gabelli/GAMCO Fund Complex. Mr. Jonas was a Presidential Scholar at Boston College, where he received a BS in Finance and Management Information Systems.

 

 

 

We have separated the portfolio managers’ commentary from the financial statements and investment portfolio due to corporate governance regulations stipulated by the Sarbanes-Oxley Act of 2002. We have done this to ensure that the content of the portfolio managers’ commentary is unrestricted. Both the commentary and the financial statements, including the portfolio of investments, will be available on our website at www.gabelli.com.

The Net Asset Value per share appears in the Publicly Traded Funds column, under the heading “Specialized Equity Funds,” in Monday’s The Wall Street Journal. It is also listed in Barron’s Mutual Funds/Closed End Funds section under the heading “Specialized Equity Funds.”

The Net Asset Value per share may be obtained each day by calling (914) 921-5070 or visiting www.gabelli.com.

The NASDAQ symbol for the Net Asset Value is “XXGRX.”

 

Notice is hereby given in accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may from time to time purchase its common shares in the open market when the Fund’s shares are trading at a discount of 10% or more from the net asset value of the shares. The Fund may also, from time to time, purchase its preferred shares in the open market when the preferred shares are trading at a discount to the liquidation value.


THE GABELLI HEALTHCARE & WELLNESSRX TRUST

One Corporate Center

Rye, NY 10580-1422

 

t

800-GABELLI (800-422-3554)

f

914-921-5118

e

info@gabelli.com

 

GABELLI.COM

 

 

 

TRUSTEES   OFFICERS

Mario J. Gabelli, CFA

Chairman &

Chief Executive Officer,

GAMCO Investors, Inc.

Executive Chairman,

Associated Capital Group, Inc.

 

James P. Conn

Former Managing Director &

Chief Investment Officer,

Financial Security Assurance

Holdings Ltd.

 

Vincent D. Enright

Former Senior Vice President &

Chief Financial Officer,

KeySpan Corp.

 

Jeffrey J. Jonas, CFA

Portfolio Manager,

Gabelli Funds, LLC

 

Robert C. Kolodny

Physician,

Principal of KBS

Management LLC

 

Kuni Nakamura

President,

Advanced Polymer, Inc.

 

Anthonie C. van Ekris

Chairman,

BALMAC International, Inc.

 

Salvatore J. Zizza

Chairman,

Zizza & Associates Corp.

 

Agnes Mullady

President

 

John C. Ball

Treasurer

 

Andrea R. Mango

Secretary & Vice President

 

Richard J. Walz

Chief Compliance Officer

 

Bethany A. Uhlein

Vice President & Ombudsman

 

David I. Schachter

Vice President

 

Adam E. Tokar

Vice President

 

INVESTMENT ADVISER

 

Gabelli Funds, LLC

One Corporate Center

Rye, New York 10580-1422

 

CUSTODIAN

 

The Bank of New York Mellon

 

COUNSEL

 

Willkie Farr & Gallagher LLP

 

TRANSFER AGENT AND

REGISTRAR

 

Computershare Trust Company, N.A.

 

 

 

 

 

GRX Q2/2019

LOGO

 


Item 2.

Code of Ethics.

Not applicable.

 

Item 3.

Audit Committee Financial Expert.

Not applicable.

 

Item 4.

Principal Accountant Fees and Services.

Not applicable.

 

Item 5.

Audit Committee of Listed Registrants.

Not applicable.

 

Item 6.

Investments.

 

(a)

Schedule of Investments in securities of unaffiliated issuers as of the close of the reporting period is included as part of the report to shareholders filed under Item 1 of this form.

 

(b)

Not applicable.

 

Item 7.

Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.

Not applicable.

 

Item 8.

Portfolio Managers of Closed-End Management Investment Companies.


There has been no change, as of the date of this filing, in any of the portfolio managers identified in response to paragraph (a)(1) of this Item in the registrant’s most recently filed annual report on Form N-CSR.

 

Item 9.

Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.

REGISTRANT PURCHASES OF EQUITY SECURITIES

 

Period

 

      

(a) Total Number of
Shares (or

Units) Purchased

 

 

(b) Average

Price Paid per

Share (or Unit)

 

 

(c) Total Number of Shares
(or Units) Purchased as Part

of Publicly Announced

Plans or Programs

 

 

(d) Maximum Number (or
Approximate Dollar Value) of
Shares (or Units) that May Yet Be
Purchased Under the Plans or
Programs

 

Month #1 01/01/2019 through 01/31/2019      

Common – 13,132

 

Preferred Series

A – N/A

 

Preferred Series

B – N/A

 

 

Common – $9.5809

 

Preferred

Series A – N/A

 

Preferred

Series B – N/A

 

 

Common – 13,132

 

Preferred Series A – N/A

 

Preferred Series B – N/A

 

 

 

Common – 18,677,778 - 13,132 = 18,664,646

 

Preferred Series A – 1,200,000

 

Preferred Series B – 1,481,443

 

Month #2 02/01/2019 through 02/28/2019

 

     

Common – 63,174

 

Preferred Series

A – N/A

 

Preferred Series

B – N/A

 

 

Common – $10.2315

 

Preferred

Series A – N/A

 

Preferred

Series B – N/A

 

 

Common – 63,174

 

Preferred Series A – N/A

 

Preferred Series B – N/A

 

 

Common – 18,664,646 - 63,174 = 18,601,472

 

Preferred Series A – 1,200,000

 

Preferred Series B – 1,481,443

 

Month #3 03/01/2019 through 03/31/2019

 

     

Common – 38,013

 

Preferred Series

A – N/A

 

Preferred Series

B – N/A

 

 

Common – $10.2423

 

Preferred

Series A – N/A

 

Preferred

Series B – N/A

 

 

 

Common – N/A

 

Preferred Series A – N/A

 

Preferred Series B – N/A

 

 

Common – 18,601,472 - 38,013 = 18,563,459

 

Preferred Series A – 1,200,000

 

Preferred Series B – 1,481,443

 

 

Month #4 04/01/2019 through 04/30/2019

 

     

Common – 5,366

 

Preferred Series

A – N/A

 

Preferred Series

B – N/A

 

 

Common – $10.3786

 

Preferred

Series A – N/A

 

Preferred

Series B – N/A

 

 

 

Common – 5,366

 

Preferred Series A – N/A

 

Preferred Series B – N/A

 

 

Common – 18,563,459 - 5,366 = 18,558,093

 

Preferred Series A – 1,200,000

 

Preferred Series B – 1,481,443

 


Month #5

05/01/2019

through 05/31/2019

 

     

Common – N/A

 

Preferred Series

A – N/A

 

Preferred Series

B – N/A

 

 

Common – N/A

 

Preferred

Series A – N/A

 

Preferred

Series B – N/A

 

 

Common – N/A

 

Preferred Series A – N/A

 

Preferred Series B – N/A

 

 

Common – 18,558,093

 

Preferred Series A – 1,200,000

 

Preferred Series B – 1,481,443

 

Month #6

06/01/2019

through 06/30/2019

 

     

Common – 14,670

 

Preferred Series

A – N/A

 

Preferred Series

B – N/A

 

 

Common – $10.5134

 

Preferred

Series A – N/A

 

Preferred

Series B – N/A

 

 

Common – 14,670

 

Preferred Series A – N/A

 

Preferred Series B – N/A

 

 

Common – 18,558,093 - 14,670 = 18,543,423

 

Preferred Series A – 1,200,000

 

Preferred Series B – 1,481,443

 

Total

 

     

Common – 134,355

 

Preferred Series

A – N/A

 

Preferred Series

B – N/A

 

 

Common – $10.1574

 

Preferred

Series A – N/A

 

Preferred Series B – N/A

 

 

Common – 134,355

 

Preferred Series A – N/A

 

Preferred Series B – N/A

 

 

N/A

 

Footnote columns (c) and (d) of the table, by disclosing the following information in the aggregate for all plans or programs publicly announced:

 

a.

The date each plan or program was announced – The notice of the potential repurchase of common and preferred shares occurs semiannually in the Fund’s shareholder reports in accordance with Section 23(c) of the Investment Company Act of 1940, as amended.

b.

The dollar amount (or share or unit amount) approved – Any or all common shares outstanding may be repurchased when the Fund’s common shares are trading at a discount of 10% or more from the net asset value of the shares.

Any or all preferred shares outstanding may be repurchased when the Fund’s preferred shares are trading at a discount to the liquidation value.

c.

The expiration date (if any) of each plan or program – The Fund’s repurchase plans are ongoing.

d.

Each plan or program that has expired during the period covered by the table – The Fund’s repurchase plans are ongoing.

e.

Each plan or program the registrant has determined to terminate prior to expiration, or under which the registrant does not intend to make further purchases. – The Fund’s repurchase plans are ongoing.

 

Item 10.

 Submission of Matters to a Vote of Security Holders.


There have been no material changes to the procedures by which the shareholders may recommend nominees to the registrant’s Board of Trustees, where those changes were implemented after the registrant last provided disclosure in response to the requirements of Item 407(c)(2)(iv) of Regulation S-K (17 CFR 229.407) (as required by Item 22(b)(15) of Schedule 14A (17 CFR 240.14a-101)), or this Item.

 

Item 11.

 Controls and Procedures.

 

  (a)

The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”) (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on their evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15(b)).

  (b)

There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR 270.30a-3(d))) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

Item 12.

 Exhibits.

 

(a)(1)  

Not applicable.

(a)(2)  

Certifications pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto.

(a)(3)  

Not applicable.

(b)  

Certifications pursuant to Rule 30a-2(b) under the 1940 Act and Section 906 of the Sarbanes-Oxley Act of 2002 are attached hereto.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

(Registrant)   

   The Gabelli Healthcare & WellnessRx Trust

By (Signature and Title)*  

      /s/ Agnes Mullady

 

      Agnes Mullady, Principal Executive Officer

Date  

    9/5/19

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

By (Signature and Title)*  

      /s/ Agnes Mullady

 

      Agnes Mullady, Principal Executive Officer

Date  

    9/5/19

 

By (Signature and Title)*

 

      /s/ John C. Ball

 

      John C. Ball, Principal Financial Officer

Date  

    9/5/19

* Print the name and title of each signing officer under his or her signature.

EX-99.CERT 2 d786930dex99cert.htm 302 CERTIFICATIONS 302 Certifications

Certification Pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act

I, Agnes Mullady, certify that:

 

1.

I have reviewed this report on Form N-CSR of The Gabelli Healthcare & WellnessRx Trust;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and


  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:    9/5/19                      

/s/ Agnes Mullady

      Agnes Mullady, Principal Executive Officer


Certification Pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act

I, John C. Ball, certify that:

 

1.

I have reviewed this report on Form N-CSR of The Gabelli Healthcare & WellnessRx Trust;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially


 

affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:    9/5/19                      

/s/ John C. Ball

      John C. Ball, Principal Financial Officer
EX-99.906CERT 3 d786930dex99906cert.htm 906 CERTIFICATION 906 Certification

Certification Pursuant to Rule 30a-2(b) under the 1940 Act and Section 906 of the Sarbanes-Oxley Act

I, Agnes Mullady, Principal Executive Officer of The Gabelli Healthcare & WellnessRx Trust (the “Registrant”), certify that:

 

  1.

The Form N-CSR of the Registrant (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

Date:    9/5/19                

     

/s/ Agnes Mullady

           

Agnes Mullady, Principal Executive Officer

I, John C. Ball, Principal Financial Officer of The Gabelli Healthcare & WellnessRx Trust (the “Registrant”), certify that:

 

  1.

The Form N-CSR of the Registrant (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

Date:    9/5/19                

     

/s/ John C. Ball

           

John C. Ball, Principal Financial Officer

GRAPHIC 4 g78693024.jpg GRAPHIC begin 644 g78693024.jpg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

&]+\.#3 MK=-%U!9H&ATR-%N3)(5?>^2NW X->W1QF38KA#B_^R,GEE*IK+O:IXFKB?:M MXRGR->U;Y.1*2]WXN;79'SN/P&?8+B_P^_MK/EG4:N*S;V"6#H83V#AE\?:N M]'^)[52I?%\'LO=^-GHGQ)=-*_:/^!6L:GA-)N]-\7:!8W$NU8+?7KRRE2WC M+L0!/<_:;:%!U9B *\;AU.MPOQIA*&N*]G@<0XJ_-+#T:[E4LETI*$YR?1/7 M='T7%EJ'$/A[CJR2P5#'9EAYS;2C"OC,'1IX6,F]G4J1?)W]E*VJ/J.OB3[L M* /G;]ISXAQ^ OAI>6T%\EAK'B^8>&=-N6$K&Q@O5VZOJACMXY)3':Z<9CF* M-W$DT(52Q /U'!V3_P!LY[A:52FYX3!?[5B$K:PI-.G2U:C>M5Y(6;2<%4U2 M3/F>+\\_U=X>Q^/IU%3QDTL+@WKIBL0I*%32,[?5Z4:N)5XM.5&,'K-7XG0_ MCK^S%HG@*Q^':>-EGT&U\/\ _"/SQ/X3\9@WD$MJUO>SS!?#0'GW,DD\SL / MGF9NM>SF7"W&N89IB6.EB:U?V\&L5@_W+A).BH7Q&U%1A&'E!'S.1\9<" M9)E.!RJEF\:E'"453FI8/&\M9R3==SBL*DU6E*;FK)-3:M8O_LG^/]-U[PMK M?@2UU<:R?A]JL]AHNI&*YMWU7P?=W%P^@WGV>]@@GB:()/;-')$K1I%;AAEQ MF>/,JQ-#$8#.:^%^J5,VHP^M4E*$U1QU*$56CS4Y3BU-.,XR4GSR]H^C-/#[ M.,!6CFN08'&/&83*,1.> JRC5C*IEU>/ M\;6\8)^T!\&3X"3PZ_BD>'?&/]G)XJ.HC0BOV.<7GVS^RG6YR+/S_+\LC]YY M>[Y. _X3?;/#S]I>G?VG)S6?^'O\ 9?L/[16)SGZNL5[3ZOS_ %+"\WMO9?O.7V7M.7DU]IR7]VY%\0/B M'^T[\/-(MM:\36/P@@T"?4K+3=4USPYIWC+5Y_#D%[*L(U>\LK[580]I$S8^ M59LN40KEUS>4Y3P/F^+6!PE?-XXN5.I.C3Q%3!4H5YTX\RH1J1I3Y9R2;5^5 M(638&IF6*PV1UL'AYTUB'A:>85:M"C.7+/$>RG6I<].EISJ, MG+WHNR@ISA[;\*/AQ:>$DU?Q7=^)IO&_BOQT;+4M:\72QPV]M?6J0[M-M=&L M[>1XK+1XHIBT2))(6#J=P1(TB^=SW-IXJ.&RFC@%E.7Y0ZD*>$O*52-5RM5J M8BI)*4ZTI*TFTN5WT,4Z-'" MTHMQI4(IIKWI2FTI3=SP.]T#QYK_ .TO\48? ?CZ/P!>6_A3PA+?WDGAC2O$ MXO[9K.S2.V%OJI"6I27Y_,C^8_=/%?2X'%99@^!LMGFF5O-:,LRQ<84UB:N& MY)\U5\_/25Y>ZG'E>FM]T?.YS@\UQG'<:>49O_8U>&04I3J_5:6+YZ:S"LG3 M]G6:C&\G&7.M?=MLV>E?\*X_:*_Z.0M__#2>#_\ XNO*6<\(+_FC9:?]37%_ MY'?_ &%QK_T7:_\ #+@?_DCZ,MDFBMK>.YF^T7$<$23W C6$3S)&JRS")/EB MWN&;8O"[L#@5\A5E"52I*E#V5.4I.$+N7)%MN,>9ZRY597>KM=GVE"-2G1HP MK5?;5H0A&=3E4.>:BE*?)'2/-).7*M(WLM$35!J% !0 4 % !0 4 % !0 4 M% !0 4 % !0 4 >%:QX-\277[0GA#QQ;Z;O\+:7X!U?1;[5/ME@GD:G=7EW+ M!;?8GNA=R[HY4/F1V[QC=@N""!]-@,PP=#A7/).%OB1XTO--\GPSK_ (7\,Z=I M&I?;+"3[5>:?%;+>0_8XKIKJ#RVC<;YH(T;'RLV1GZ:MF&#EP?EV51K7Q]#, M,37G2Y)^[2G[7DESN/LW?F7NJ;DKZI:GS7]GXO\ UREFOL?^$_\ L6&$57FA M_O"QTZSI\G-[32FU+GY.3IS.=,7X>IX6EC? MQ9X?\-"*[EU>:^E;=JER9F,<<<' M]C>?Q)E"*]'),3DE;AC'9+FF;?V75KY ME'%PDL-7Q-Z=/#4J2TI1Y5S2YUK-27+\-FF>3Q'AL]I<3Y-G>3Y-_;%+!995 MPM2'UO#X3EJ5,3B*EN:M+F=H3A+W82B^:W,FFEL_\+'_ &B_^C;[?_P[?@__ M .(K+^QN$/\ HLI?^&K%_P"97]N\:_\ 1"+_ ,/6!_\ D3L[G7?BKJ7PPU[4 M$^'X\/\ Q%EM[^RT;PO'XGT+5%CEEVV]GJ;:V+FVL0J+*]R8FD5O]'V M34P61TLWP>%AG'UO*)2IO$XIX:O1Y(7;JTU1<9U6W&*A&48OWJB>T6SW<%F& M>3RK&8S$Y$L#FU"-;ZK@7BJ&(C6J1IQ>' O#WAB2*"XO[.S^T:S>.B2O>:Y?.UYJURTK[FD#7LTJH2Q(CCC&< M**.(;9OB\92;IX;F5/#P7NJ&'I)4Z,5%646X14I))>_*3ZF7#.3RR;)\+ MA<2_:X^IS8C&5)2YY5,77DZE>4IMMS:G+D4KZQ@F=AK'A_2-/"O7HU*=6C5E3K4)1J4Y)OW9T MY*4);_9DD_D>_P E)IPJ4H5*"Y?!?C.R,9\*ZKJ&D>&=6^W6%VNN>%4E,FCW>RTN9)+)XHG:W\BY2%UCAA& MW@X]_BW%Y?FF*AF>7SM7S'"PGC*').'L,9R$_#)/VB_A7X>NO"UC\$+/7K4Z_K6K0ZC-\0_"6G/(FIW1F5/LPU"7:%51R6 M!YY4$5]1G$N$<\K83%UN)98.I1PE##RIK 8JJDZ47=\W)%;R:T36FC=SYS R MXPR/$YY1PG"BS'#8W-L=C:59YE@Z%Z>(JWA^[E*4HWA&,O>Y9+FLXQ:/7?#W MCKX_7VN:59>(/@98Z%HES?6\.J:S'\0_#6HOIED[A9[Q;"UN#+=M&F6\J,%F MQ@5X.)RKA.EAJ]3#<53Q&(ITYRI4O[.Q-/VM11;A3YY+EASR2CS/2-[O1'KX M;.>,JF)PU+$<&1PV'J5J4*U;^U<)4]C2E4C&K5]G'WI^RIN4U"/O2Y>5:M&_ M\?O"NO\ C7X3^*O#/ABP_M/6]2CTU;*R^U65EYQM]6L;F4?:=0N(+>/;!#(W M[R5<[<#)(!\[AC&8;+N(PPN%K3E5GRRGRQ="M!/EA&4Y>]**M&+>M M[639[O$.%KX[A[.\#A:?M<5B\'5I48HZ-;S M6>CZ3:W">7/:Z;8V\\>Y7V306L4,IR<79I-733LTFNJ.K+*-3#9;E^'JQY*M##4* M9KXI\L%]J2/G^,\KQV:X+(Z.7T/;U,'G^58VLN>G#DPN&==UJMZDX*7)SQ]R M+E4E?W(2L[>]5\N?7'@OB[P7XEU/X\?"GQG8Z;Y_AKPSHOBRTUO4OMFGQ?8K MC4]/NH+&/['-=)=7/F2R(NZ""55SERH!(^HRG,<'A>&^*I&4;4HS<;7FHQ:9V_Q-^'&C?$_PS)X>U66XL9X+B'4= M%UJQ;9J.AZQ:DM::C92 J0Z$E63$XII4W&%+$1Q/U#%.FHICZ09VT[X?>#)6NH+Z2XMS; MM)XIU>[1A>A%>0K!!N0.(Y(VA9#OY,9B>&L%@:^"RG#5*BHSQV,BJ:HQ M4E*V$H0:<)-QC>I-\UN:+YX2Y5VX7#<4X_'8;%9KB:&3X#!5/:0P.!DZM2O+ MDY+8S%5()2IQYIVI4J<8N\9/]Y"%121^"_$?B3XXW'C3Q1I:VOA/P1H TGP# M%-=:?=C4]5U@$ZYKWV6VNI9+)HH UHJW44+LLB,H^0XBEF.#P'"]7 X2MS9I MG&)4L;:-2/L,)AG^XH<\H1C/VL_WS]G*2C[T);HUQ>78W,.*<#B<31Y,ER'" MRGA6Y0?UC,<7:-:KR1J.<8X:A&-&/M:4?WJ=2DW&3;]O^QVG_/K;_P#?B/\ M^)KYKGG_ #R^]GTW+'^5?K[;ZZMUNI+"ZQ(8X?,F98(D1&!./I\IS+!SR3.LCS2NZ-*JHX MS U)1J5%#&TERNG:G&/A3XSL=-\_ MPUX9T7Q9::WJ7VS3XOL5QJ>GW4%C']CFNDNKGS)9$7=!!*JYRY4 D+*% MX;XIP%>MR8O,?J'U>GR3?M/88A5*GO1BX0Y8*_[R4;[1N]".(,KQV-XAX'QV M%H>TPN3XC-:F,GSTX^QAB<%2HT7RSG&=3GJ1E&U*,W&UYJ,6F>U:MI6GZYIE M_H^JVL5[IFIVLUE?6DZ[HKBVN(S%+&X]U8X(P0<$$$ U\S3J5*-2G5HSE2JT M91G3G%VE"<&I1E%]'%I->A]:XQ<90G"-2G.,H3A-*4)PDG&<)Q>DH2BW&47H MXMIZ,\1^#7A?QY\.;W7OA[J]I-JWP^TN9KSX?^+7U'39)[;3[B02/X9U*Q:\ M%^)+9Y&,,PM6BPDJ^8J>2B_5<09AEN=8;!YO&<<-GLDJ6/PRIU%"M*"Y88NE M-0=)#I@*L M)S5><82/#P1CC58G" MXW$8AI83$8B\9RFH*].*@KQES?&VMFDSCSBEQ!@N*H9SE&1?VQAY933P4E]= MPV$Y*BQ=6O+^,W*5H\FT.5\^DKQ:.C_X6/\ M%_]&WV__AV_!_\ \17/_8W" M'_192_\ #5B_\R_[=XU_Z(1?^'K _P#R)[?X2U'Q#JOA_3[_ ,5>'5\)Z].L MYO\ P^FK6>N+IYCNIHH%&J6 $%UYMLD,V8_N^=L/S(:^:S&A@L-C*M'+\=_: M.$@H2;E3U^+EYEHT?3Y3B"IULTRW^R<9*512P MWUBGB>2,:DHTY>VI)0E[2FHU+)7ASVUWKSWD>CV>GZ#X@U^\OGT^)) M[P16OA_2[V4>5#(KL711MW$9"MCT,ORK&YG]9^I4X2C@X0G6E4K4*$*<*DG" M#E.O4I0]Z:Y5:3=[+JK^?F.:8+*:>'J8VI."Q57V%&-.A7Q%2I55.=7DC2P] M.K4;5.$Y-\EDHO4PX?C-\.GEAAN=9U#11/-%;PW'B?PKXN\)6$D\S;(H5U'Q M-H5A:F5FP GG9R1QR,];X),HY93JUJ^$I0<4ZF+P6-P=).C33A!':O$M;3:W0]Q--)IW3V:VMT"@84 % !0 4 % !0 4 % !0 4 % !0 4 M % '#_$'Q_HOPX\/G7M9CO;OS;RUTO2]*TR#[3JFLZO?.8[+3-/M]RB2XE96 M^\RA51B3P ?0RK+,5F^-IX'"**J2C.K5G)1A&Z2UE.481E*/F MUE\;-=TW6M$TWXD?"[7?AWIWB?4H-(\/:_/KFC>(M.EU&Z ^Q6>LC2B'T*YN M'RB)+YOS#YBJAVC]R7#6$Q%'$O)\]H9KB\%1G7K8:-&MAY^SI_Q)8>55:2;LOH&ODS[ *-OD!Y7X!^)G_"9>)/B#X4OM$_X1_6O &MQ:=- M;?VD=174]+O8Y)=,UJ)CI]H8$N$A<^1MFV I^];?Q[>8Y-]2RO)$?$/BZ_C\ZU\/Z7 M=:BUN)1 UU)"G^CVB2E'\IY[AHH5;8^#*#M;&#YV!PE3'8W!X&CI4Q=:G1B^ MW/)1[%ZK<];%8BE@L)B\97;C0P5"MB*C2N_9T*4ZL^5:7DXP:B MM+RLKZF/\+?B#9?%#P-HGC2QM#IRZI'<+<::;D7;:=>V=U-:75HUR((//VR0 MEED\F+7D52%2$9QER\T^6UW&2YI6E M%J^AX_#.?4N),HH9I2HO#.I*I"I1<_:.E.G-Q<>?EAS*45&<7R1]V:TN4/BA M\2?^%=VOAE+31O\ A(=<\6^*-,\+Z+HPU'^RS-/?N5ENWNA87A2WMDV,^(&_ MUB@LNT=+V^)Q-3EA3]HJ=7V=J<:M3F]G)-P4-' M--97Q?\ BKJ/PQB\(1:3X0/C'5?&'B&/PYI^F+KT6@$7L\6ZV"W=QIMU&WF3 M%8_WGDJN[_P TIQ46GR7_ M/X]_]&S7'_AV?"O\ \JJ]+^P^%/\ HM(_^&K%?_+3 MRO[?XR_Z()_^'G!?_*CT7X?>+/B#XEEU1/&_POD^'4=I':-ITLGB_2?$_P#: MKS-.+F,)IEI";/R%CA.Z3<'^T87&PY\G-LOR?!4Z$LLSU9O.QDV99YC:M:&;<.O)*<(*5.?UZAB_:2O9PY:,(N M'*M>:6CV1'X*^)7_ E_C3XE>$/[%_L[_A7>I:1I_P#:/]H_:_[8_M2VN[CS MOLGV"'^S_*^R[=OG7.[?GS]E M;EO[2IS_ !6AL>HUXA[YY=\1?B5_P@&J?#W3?[%_M;_A//&%CX3\[^T?L']E M?;"@^W^7]@N/MVS?_J-UOG'^L%>WDF3?VP\U7UGZM_9F7XC'?P_:>T^KI/V7 MQPY.:_Q^]R_R,\#B+//[ PV68CZK];_M'-<#EG+[3V7L_KCJKV]_9U.?V7L_ MX=H\_-_$A;7U&O$/?&2/Y<BN5"// M.$+\O,TK]KNVWD>%?!7X\Z#\8HM9M8;'_A'O$6A7,B7>@S:@NH/+IXE\J#5+ M.Z^R6IN+=I!YA@Z_M?K>"Q<(VK1I^SY*K7,Z M,X\]3E?+[T)K3]E*HI^VHTZCI^W MIODAIS*U2%FZ;<;RDI)GNLC^7'))C.Q&?;G&=JEL9P<=*^2G+DA*5K\J;MZ* MY]A"//.$+\O,TK]KNVWD>>?"GX@?\+.\%V/B_P#LG^P_ME[J]G_9WV_^TO*_ MLK4[K3?,^U_8K7?YOV;S-ODKMW[)D>;_P!LX;$XCZO]6^KXO%87E]I[3F^K573]I?DA M;GM?EL^7;FEN>+Z+\?OB=XJDUV3P;\!)?$6EZ%XAU3PY+J2?$K1-,$E[I4JK M+_HFHZ'%+&6BD@DP/,4>;M#L5-?05>%P>,_'6A?#_PO/XI\52R6-G; MK;I]E@3[7>W-_<@+!I=A"FW[7>22Y10"J_*SLRHK,OSF!RW$YECZ>79?'ZQ6 MJRDH/X(\D+MU9M_!",5S2;NUI%*4G&+^JQ.88?+\NJ9GF4E@J&'I1J5[OG]F MY,6\.M"+A+IO$FA)XA,) M&]=WA/R3&^7;GFOH7P[D=.]"KQ?A(XR,N5PCA\1/#IK1_[6K0L MGIS\FTW4-.US3+C2]1TW4[5(VNK"YBF!CDEA\U S M6\LR DKNW*RKXF;Y1B39SA\ZP]2K0H8C"5,-/V5>ABJ$Z%:C648S=.<9*SE&,HMN$I+57 M:V/.]<^-]Y)X@UGPM\,_A[KOQ-U;PY+]EUZZLM0L/#_AW3+\?>TV37]35XI; M],'?%'$V"" 6*L%]+!<.0E@\-F.;YI0R3!8R[P_M(5*V(K07_+V&'I>][)]) M2E&^CMRRBY<&8<22H8W$Y7E&58C/,SP<8O$4Z,J5##X>!&=[ M.#7='CV>1XUZWB.&J+PF)QN3YUA,VH8.+G6@N;"XB%)6_>.A M7:;CJEI)MR:C#GEH88?B?$4L1A,)G608W)JN-E&E2J>YC,+*O+14?K&%PVMWX_WVNB:1J.NZG)YOAA8%^S M:7I-M/=7.UI S^5$VQ%=VPJ,1KPS0EB%?%&H^+_$_A^]AM-&\3^&M1\(6 M]K8W.+)]?O9/%=O9,VFV,TJ2LUI%=3;XE6.,L1B,OR/$8*OA4U'?;%<0X3$4J^78?+\7BL M?CL-B(4,'B<'B,%'$1.IT(.A3=6+Q#INI4C3ORTY2Y8ON-3TGQOX5 M\$^%O^$9UF/4=3\$:1IT6LZ3J*V,=CXTL],TV*UU""75+JT>YTC4&6&2XM;F M.:*,2A5NDDB<[.!XW*\;F^8U\=A71P69UJTH3I\WM<"ZM64Z=6G3A-0K*%U& MK1FIK.4)5*4* MMG[*M3Y9TZBIRJ>TI\].65X"\>:G\6M2A\3^&+Z31OASHY>T>*2WTV76?%6O M&%#>6EXD\=PVBZ-IIE5083#VKXCE?+3E>G0I?Q8.M+EI(JJ,<-.-"$ZN(]NKYD^I"@ H * "@ H * M "@ H * "@ H * "@#YA_:@N],L/#GA/5EU:P@\7^%?&6B^*_"/A^X,T]UXG MOM,G\N72;73[..6XF:5)P!(L11'"AG3?N'V/!"KO-L12CAJE; XS!8G!8VI" MR6&P^)@KUY5)M0AR.G?WI)RCSI6=:%2=-0A&5ISISGRP4F(=5_:>?0[;3=&_X1/P'X1\ M5:9JWBN76;VRF\4WNO:&1I5QE?%+,,QQ>%K4\OC0A-894JZY/K56O-1C.2AK&C1]HDW[TW&49KREF6(X M[P#H8B@LW>*E!8F$\/4A7>#P^&A*52/-6IQ4L1B%1:C"48TG+G2 M^L+/6-)U"ZU&QL-3L+R]T>>.VU6SM;N">YTRXEA6XAAOH(I"]I(\#K(JR*I9 M3D9%?!3H5Z5*C7G1G"CB%)TJDHR4*BA)PGR2:M+EDG&7*W9JS/T&->A*M6PT M*T)8C#Q&4SAFN%5KOV:O3Q<8]5&$.>K)+1SJ1NKV9\-Q%_PD\3<+<0IJ&'QKGD6 M-;DXQM7%0NKZNLFW[JS-'"BDX!:/'L<.$(K"5LUX@FOCLW4YENDTSHXUFZ^78#AZE+EK\48ZC@Y)2E":P6'E'%X^K#D]YNG"G1A)7 M2<*TDWO:K\'XU\"_%/XM?"L*EMIEQ>6OQ'\)6Z_)&NFZZJ6NL6]M'P$M[74$ MMHE5!@?/P,\Z9S*6:\,Y!G,FYXG .IE.+D]7>E>KA92>[E.BYSE)ZMR1AE5. MGDG&&>9/2C"A@\YH4,(:1IJ.B6D4D ^('[2\ M$8_?:'\%O#)GDYW0_P#"8>+%*0JR_=+PZ4K.#U22UXYYHPO_ D\%XW%?#B> M)L4L-2=K/ZG@GS5I)[J]=NG+I*$T5F7_ J\:9-EB?-AN&<+/,\2E+3ZYC+4 ML'2J07VJ=""Q-*3=U[225KN^/^U'K&G>'M1^!VNZQRLD2XN9O(M8I)IMD,;MLBC=VQA5)(%=' 5&IB<1Q%AJ,>:MB,DQM*G&Z7 M-4J?X>KBLIQ7UO#T*KH3E[.M2Y:JA3J. M/+6ITY.T*L'S)./O6O=-+PSX+?\ ):/VE/\ L8_"7_INU6OI<[_Y(W@C_NJ_ M^I%$^7RC_DXW'G_8)P]_Z@2/J*OB3[X^7?VBO^1H_9[_ .RP:)_Z'#7VW!._ M%/\ V(,P_P#2$? ^(G_(MX9_[*G(_P#TK%'U%7Q)]\0W'_'O/_UQE_\ 0&K. MK_"J?X)?DS2C_&I?XX_^E(_/GX<_#O6;_P"#OA#XG?#O;:?$OP3K/C">T15Q M%XIT5?$VJM?>&=312OVA)8?,$.X@AG9%92ZO%^O9WG.'P7$6)RO-8NMD.:8/ M 0Q$.N'J?5:2IXNCORSI-)SLG>,5*TG34)?DF5Y'6S/*,3CLKJ+"\191G&:U MSU?2ISB]T36;:/;?:7>1D!DEBD(*L57S(WCD ? _.>(&FFJN M%Q-.252C4BTI+E>L6TFXM72DI17F_P"RG_R1?1/^PUXN_P#4GU2O?X__ .1_ M+_L"P/\ ZBTSQ>"/^1;F/_8WS/\ ]2I'B7P-^./PN^&VG?$#0O&GBC^QM5G^ M*7B_4H;7^Q?$6H[[*=[*WBF\_2=)NH5W2VLZ[#(''EY*@,"?H.(>&LZSJAPU MBC2J17OTYQM)J6E[6:;^AM!_:5^"GB;6=,\ M/Z'XT^VZOK%Y!I^FV?\ PCGBRV^T7=PXCAA\^[T&*&''KXK$99[.AAJR39]9A_$#A'%8C# MX3#YMSU\75IT*4/JN-CS5:LXTZ<>:6'48\TY17-)J*O>32396_:$\&^)O$_A MOPUJOA&S35]:\">,M&\9P^'Y91"FNQ:2TIEL%+'8TY#JRJWW@KJN790T\)9E M@\LS2M]?DZ6$S#!8G SK1CS2H?6%"U5)7=H\EFXIM'R M^TL;@\7A,M"U&Q$,RDJX^WPV\D"V^Y3MFN#; C&Y5)VUU5^",W MY9ULLGA\ZP<=8U<)7IS;72].4E+F[PCSVULVEV.HZ=?(+BUO]-N(+ MJSNHWZ307-L[1S*V/O*QZ=:^3Q&'KX:I4PV)I5,/6I7C*G4C*$X/LXR2<7K? M9=SZ_#8G#8NC#$X2M3Q-"LE*-6E*,X35DDU.+:>B2WT2MT/CCPAXKU']G&_\ M8>&?'_A/Q%<^$M8\7ZQXIT7XA:!ILFKZ:]OJWE,\.OB$^;:7,2P("3OD+,X$ M9C197_0,7A*'%^"R>MEN/P]#,\OP-' ULOQ%1492E1#LWXA>.R[$XO)\\S'$YI2Q^$HRKJA[=*52CBZ<+U*7LN6,8 MS::G+GG!.#;C]'^"?BQ\-_B/@>#_ !5I>L74*-.=.8RV6KP(F8WF.E:C%!=K M&NXJ95A*?/\ >PPS\GF?#^=9-KF& JX>GI'VBM.D[ZJ/M:;E3N[747)/3:Z= MOJV]C_8^-EC.7DY_:WPN(POL[\T?9V]OS\]I_#R\OO!;3QI9V31WUSH M/B/0[K^T/#'BG3T1]1T+40I1G1'95O=/GC)BNK&5O*N(F*/@[66,KS*KEE>4 MXTXU\-7C[+$X:I?V6)H-W=.:6L91:YJ56-IT:B4X/=2US++Z.98;ZO5E.C4I M357#UZ34:V%Q$$U"O1DTTI)-QG!IPK4I3I5(RA)HB\3>#=2\6Z?HVC:SXA5- M&B,4GBVQTO3);!O%A@1"+#[2VJS-I.AS7"LUS9J+J2>(B#[0B%S)>#Q^'P.* MKXO#X/FJQO\ 4O:U%4CA9-NU6U=.;45'/$8+%8O T M<%6QW*Y MT:4.3D?U_P!E?W56>*4[[56E42O3Y3)^-DUC\//&6D^.OA9JUJOQ3U^YATO4 MOA]I\,FJQ?$"Q<$F?4M(TY_,M;NT4&5;\^7D(1OW;BU\,*MF> Q>39O0G+A[ M#TZE98V;5/\ LNI&+:G1K5%RN-1Z2PZYKM\RCR\R9Q:L/EF*P>>Y9B(4.)I3 MHX>GA(^\\ZHN<(/#5Z,'S-T8/FIXRR5&,8TJD]<.Z7?_ +,C:#=> KK5[34V MU7Q?KFMW^J_$66[A:UU6T\67$C&YTN^LI29;2&SC"PP*<(Z*TJ >:P''QK"O M0S#"X2-%4,HP>&ITLLY)*=*KA4D_;QJ1]VJ/62]V,G)1C)[\#5:6*PF M8X[$57+/\;BZD\VISA*E5PV(BW"&$]E4;G3HX:G'V="+]U)2LHN\(_1M?&GW M!X?^T/X3N?%'PNUQ],#KKWA=K;QAX?FB4-/#J?AY_MH\CC(E>T6YC&.[K7T' M"N8PRO/LOQ%6SPM:?U7$QD[1EA\3:E-3_N1DX5)>4#P^)LJEG7#^:Y;2NL34 MHNKA7&RFL7AFJ^'Y&](SJ3I^PYM&HUI:J[///@GX@3XP_$3Q!\7/(=-,T+PI MX>\$:"DJD"'5+VUAUWQ<45AQ)#>3V]L)!]Y'.#M;)]_B+ OAG)89%S)U\RS# M$XRJUN\)AY/#8&[_ ):L8RK.+^&:UU6GRG#69KBS.<-G-G]7R+*L/ADG;D_M M/')5\?."6MZ5.-+#.6B:C>*LTS2^.]XGPZ\7_#7XT[9O[/T.]O?!_B\6\9DD ME\.^(()6M97106D6TU&,RJH!)>1 .2 >'A6,LQPN?<-KE=7,\,L3@U)V2QN" M:G&*;TBZU-\DI/2,(-O2[7J\86P']@\31X>7-AN'L+2P::VE745/$U&NDW4?)/NZ9 M/!BGC:&:<2UH2IUN)<;5Q-.,^7GI8*DW0P-%N.CC3HPO!W?NS1SW[1NS_A)? MV??,V^7_ ,+?T7?OQLV[H<[MW&W'7-;\$WYN*+;_ -@9A;UY8V.7Q$_Y%O#7 M_94Y'^>*/I3_ (E/_4._\EJ^._??W_\ R8^[_=_W?P+,#6V"EJT&U3EE@,> M3QDK'T)QU]JB2FKG0^6_@[>6EI\:/VDA=75M;;O$?A M/8)YXH=VW3M4W;1(PSC(SCID5]MG,)SX-X)Y(.7+_:E^5-V_VBC;;;8^"RF4 M8>(O'?-)13PG#]KM+; 2[]CZ:_M?2?\ H*:=_P"!MM_\=KXSV%;_ )\S_P# M)?Y'W?M:2_Y>15O[R_S/FO\ :,DCB\2?L^R2.D<:?%[1'9W8(B(K0DLS,0%4 M#G).*^QX)3YN*4EK_8&8)+K?EBDK=SX7Q#:_LWAEK;_6G(W?I:^*=_2VI]*? MVOI/_04T[_P-MO\ X[7QOL*W_/F?_@$O\C[KVM+_ )^1_P# E_F2&YMKJTN' MM;B"X18Y5+P2QRJ&$9.TM&Q ;!!Q[BL:\)TZ513BX7A*R::TLUUL;8>495J7 M+)2Y9PO9IV]Y=MCY_P#V4_\ DB^A_P#8:\7?^I/JE?;*Y$)&"4?Q+J;*2#TX(XI^(473X MAJPEI*&$P47ZK"TT_P C/P_KT\3DN*Q-%MTJ^9YA5@VFGR3Q#G%M/5.S6CU1 MA?LM_8?^$:^(WVG[)YG_ M_QICS_)W[=NF8QYG.W.?UK7C/VEN%N3FM_8.! MVOOSU^QS\%\O]I>(/-;_ )*G,K7MVH]SZ>5M+0AD-@K*)]#>?4+KPKX@\.3VYE>>\GTG4]'DMG3)E:69Y M+G5HSA)=?BA*+6][IK<^=_P!FM+.SUKXT+X2,C?"N#Q;:_P#" M&>3Y]Q8F\CL[AO$2Z,27::Q67[$J>5N# 1[&U5P2P_LI+ZJ ML:Z'^W+#2OR*$:S:ER/V*C[)4K4TCV?P5\7_ !X]^U6^C:W#;ZI8W-Q:7_A M[6@-(U^SEMY6A;SM)O628Q,5!#H'4;@K%9 R+\[F/#V:Y9"C5KX9SPU>$)T\ M10:K4)*<5*WM:=X*2U33:O9N/-"TG]/E_$.4YAB,5A,/B?9XS!U9TJF'KQEA M\0O9RY5/V-90J*\!_:$TWP=;Z_P##FZ\%0:1;?&*?QWH0 MTC^P$@CU>YTT2R'4I-;CT[:\FE+$1OENA@(9%#>6917U'!5;,&\RI8Z567#, M,#B7C%6;>'@^5/Z&7+!86MA84H<5RQ>$CE, MZ22Q=2JJ\>>,G3M5EA(TI5)5.?\ =0J.FKQE4M+[+K\]/T4* "@ H * "@ H M * "@ H * "@ H * "@ H * "@#B?&?PX\#?$*VBM/&?AK3==CMPPMI;E)8; MVU#_ 'UM=0M)8;JU5B 2(ID!(!/2O0R[-$DX M3MTYXRMK;#?"6EZ+M:YXBTC1+#3]:\2-;OKFHVT(CGU%[ M52L+3$':"-S,VQ5WNQ=]SG=7%5Q^-K83#8"KB9SP>#--S^+E7;317 MM%744DVCT(9?@J6.Q&94\+3AC\5"%.M7C%*I5A2^!3:^)I67,_><8PBVU""C MTE*10T;JR.C#*LC JRL#U!4D$4FDTUT>G]6'%N#4HOE<6FFNC6J M?R.8\'^"?"_@#2/[!\(Z3%HVD_;+J_-I%/=W(-W=N'N)FFOKB:9BQ55"F0JB MHB(%1%4>AF.9X_-:\,1F&(>)K0IQI1DU&-J<+\L;0C%;MMNW-*3(J1AS6=6I;FDE)OE5HQC&$;0A&*C",8I(L>*O"GA_ MQMH5[X9\4:&>%TFBC8-%*C?+C."0<<% MC,3E^+H8W!U70Q6&DY4YI1ERMQE!^[-2A).,I1:E%II[&^+PF'QV$Q.!Q=)5 M\)BZ;I5:;;2G!M.UXM2BTTI1E%J4)1C*+4HIK7L+&TTRRL]-L($M+'3[6WLK M*VB!$=O:VL206\$8))V1Q1HHR2<+6=>M5Q-:KB*\W4K5YRJ5)O>4YRT*=.*A"*O=VC%):MO35MG'>//AGX(^ M)EE8Z=XWT3^V[/3+I[RRA_M+5]-\BYDB,#R>9I%_:O)F)BNV1F7N!GFNW*\W MS')*]3$Y9B/JM>I3=*4O9TJEX.49N-JL)Q7O1B[I)Z6O9LXLWR;+<]PD<#FN M&^M86%:%>,/:5:5JL(5*<9D*M18?\ #)W[/_\ T(/_ M )=7C7_YHZ]W_7WBS_H:_P#EK@__ )G/F_\ B''!G_0F_P#+O'?_ #2>A> ? MA%\//AA+J*A4?ML15YHQ?,E:M5J)6>MXI/S.8\1_LX?!CQ;KFH^(_$/ M@W[?K6K3_:=0O/\ A(?%=I]HG$:1;_L]CKD,$/R1H-L<2#C.,DYZL!Q=Q#EF M$HX' YA[#"T%)4X>PPT^52E*;]ZI1G-WE)O63M>RT21SYGP7PUG&.K9CF66_ M6,975-5*GUC%4^94J4*-/W*5>$%RTZ<(Z15[7E>3;>*/V3O@ I!'@'!4Y'_% M4^->,=/^9CKLCQ]Q;!IK-K.+37^RX/=;?\PYY[\-^"[6_L;3_L+QW_S4>F>. M?ACX'^)-AI^F>-=$_MFQTJX:ZL(/[2U?3OL\[0FW,GFZ3J%K)+^Y)7;([KWQ MGFO"RS.BG=)/2U[71]%F>1Y M7G&!HY9F6%^L8*A4IU:=/VE:GRSI4ZE*G+GI5(5'RTZLXVY_K[Q9_T-?_+7!_\ S.?._P#$..#/^A-_Y=X[ M_P":3U3P/\.?!OPWTB[T+P7HW]C:5>WLNHW5K_:&JZCYMY-;V]I)-Y^JWUS, MF;>U@38DBH/+R%#,Q/AYMG&8YY5IULTQ/UJI1I>Q@_9TJ=J?-.?+:C"FG[TY M.[3EK:]DDOHI&*BI7KU*C5E%*R:6FUS3 M\*>$O#W@?18/#OA?3_[+T>VGN[B"S^UWM[LFO[J6\NW^T:AWK\E.GSY2BH07+3C"/NQBE>UW:[;>IU8'+\ M'EM*I1P5'V%.M6JUYQYISO5K26\]I=0Q7 M%K-D9E*D$$$@UQ)M---Q<6FFFTTT[IIJS335 MTU9IJZU.U-Q::TY=C!\)^$/#O@71+?PYX5TU=)T6TFNY[>Q2YO+I(9+VYEN[ MDK+?7$\NUKB:1@AD*J&VH%4 #MS#,<;FN(>+S"N\1B'"%-S<81;C3BH034(Q M3:BDG)KF>\FVVS@R[+,!E-"6%R[#1PF'E4J5?9P>!?.O+^ZN+RZF_X2?QC'YMS=2O//)Y<7B%4C MW2NS;455&< "O=H<;<3X6A1PU#,^2CAX0I4X_5L(^6%.*A"-Y4')VBDKR; M;W;;/G\7P%PGCL7BL=BLJ]KBL96J5ZT_K.,ASU:LY5*DN6&(C"/-.3?+",8J M]HI))%7_ (9._9_'_,@]/^II\:]O^YCK9FWNG/I%]86E]IC[-1Y5"2E?F7*K-2O=;W/&9_V9_@7<7ZZE)\.]*6X1MRQP7F MLVUADYX;2K;4TLG7G[K6Y'MQ7T=/C/B>E1=".<5G!]9QI5*FG:K.G*JO531\ MS6X'X3K5X8B>18:,X7LJ:G2IZJWO4:4X49^2E"5GJK,]ETK2=,T+3[72=&T^ MRTK3+&(0V>GZ?;0VEG;1+DA(;>!%2-2:^>Q&(Q&+K3Q&*K3KUZC MO.I4DYSD]M92;;LM%V6BT/H\+A<-@J%/"X.A3PN'I*T*=*$80BO*,4DO/N]6 MS&Z\6>#='U6]9!&VH^5+8:F\:C:J/J>FRV]TZJ/N@S';_ XK MT,NSW.,H7+EV85L+33YO9J7-2YNK]E-2IW?5\NO6YPYGD63YPO\ A3RVAC)1 MCR*I.FO:QA_+"M&U6"6Z49KE>JL]0\%?"'X:_#N5KGP=X0TO1[QHVA.H#[3? MZF(7P7A&IZI<7-TL38&Y!,%;:,@X&+S+B'.LVA[+,,QJUZ2:?L_=ITKK9NG2 MC"FVNC<=.ASY7PQD&2S53+,KHX6M%.*JVE4JJ+W7M:LIU+/9^]JM'H>D5XQ[ MP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M4 % !0 4 % !0 4 % !0 4 >"^*_V:?A%XT\0ZGXH\0Z#?7>LZO-'/?7$6NZ MQ:QR21016R%;>VO$CB A@C&$4?=R>237T^7<89_E6#HX# XN-'"X?GY(.C1F MUSSE4E[TX.3O.=8^MF68X"5?&5U2C.:Q&(IIJC1IT*? MN4ZL8+EITX1TBKVN[MMOYM^#O[._PJ\7:M\6;77=#O+F#PI\1=3\/:(L>M:M M;&VTNUC1H8)&M[M3<."3^\E+.>YK[+.^+\^P66<,8G#8N,*N99?'$8ANC1:E M5;5Y)2@U%:_#%)>1\5E' O#.)SWBS U\!*>&RK%T*6&C]8Q"=.$Z'/*+E&JI M3O+6\W)K:]CZCN_A]X7^&GP@\>^'/"%E-8:2WASQ;J)@GO+J^?[5<97BLQJJM7IU\'2C)0A3]R.*C-+E@HK24 MY:VOKY'Z5D>199P]0JX3*L.\-0KU95YQ=2I4O4=.G2#/$VNZ!?76KZQHZ7=_<1Z]K-LDLYGG0LL%O>)'$-J*-J M*!Q7VO$_&7$&69]F.!P>,C2PV&G&-.+H49-)TH2?O2@Y/63W9^:<'<#<,YKP MWE>88[+Y5<7B(U74FL1B8)N%>K3C[L*L8JT816B6U]R_\1_AK#^SYX=7XE_" M;7=?T2#PU?:>VM^#M0UJ]U/PUXATR]O[>TN+=[2]>1H+S=."LH9BH+&/9( U M:*4&G%K?ENY0YH2 M]?..&J7#&4XG.N%\5B,LKY-#ZQ+#3Q-:K@L52]K!5:56E6E4Y9M2\?:8[ S2>VJO;9 M'U+%_JX_]Q/_ $$5\/+XI>K_ #/NJ'\"C_@A_P"DH^9?VJ_^1(\'_P#94O!? M_HZ]K[+@'_DHG_V+\=_Z33/D_$#_ ))#-O\ '@?_ %884Z7]HGQGKG@OP%;O MX>OUT74?$7B31?"J^('163P_;:M)*MUJOSD*DD4$+A7)&POO!#*".'A'+,-F MN>4<-BX.MAZ%&OB948MJ5?V$8N-!-:^_*46TM7&,H]3OXMS3$Y+PYF.88.4: M6*I^PI4ZLXJ<*#Q%>G1>(G&7NN-*$I./,G'VKI\\91YHO%B_98^%[PPW.H3> M,-4\1K"HE\87'C'71KTTY&7NUDCO!;1NSY<*+N?&^=0E.GAH83!X M+F?+A*>#P_L(Q6BBU*FYNRT;YD].FQYU+@;))JC7QM7&YECX02>-JYAC/;2; M5Y2BZ=>,8*3U48JR5EKN>B^"? &J>&_#6L^%/$GC36_'>F7TEW:Z=/KBPIJM MAH-U9):G3+C4H/WVH3AFN#]JD8'#H$2,)@^1FV:8?,,1AL5A\LH977IQ3K+# M\RI5:T:CDJL:3]VE'E4%R*]Y*3E*5U;V\DRO$Y-&O0GFV)S/#JI"6%6*Y)UL M/3C"*=.=:,8RK-U%)J4DE&'+%134I2^37]:N$ANK:W:2%V@GO6CE"L =KJ0>XKZS)^.>),7FV582OC82H8 MK&8:C4C]7H*].I6A":O&FFKQDU=--;H^-S;P\X2PF3YSBJ&6RA7P>78_$4I? M6<4^6K0P=:K2ERRK.,N6<(OEDG%VLTTVBW\-OV6O@QXC^'O@C7]5\.W\^J:U MX4T#5-0G3Q!K<"2WM]IEM&. N%LQX?RC'8S+I5,5BL-3 MJ59K$XF"E-K5\L*L8QOVBDNR/LFUMHK*VM[2!2L%I!#;0J26*Q01K%&I9LEB M$4#)Y-?F]6I.M5J5:CO.K*4Y.UO>DW)Z+1:O8_5*%&GAJ%'#4ERTJ$(4X)MM MJ$(J,5=ZNR2U>K)Z@U"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * M"@ H * "@ H * "@ H * "@ H * /F+]G;_D/?'O_LL&M_\ HJ.OL^)O^1+P M3_V*8?G$^-R'_DJ.//\ L/PW_J,>T_$C_DGGCO\ [$[Q+_Z9KVOE<#_O^7?] MA>$_]2*9]I'=?/\ (^4_@U+^TLOPN\%CPA:_!9_#2Z,G]CMX@;QH-:-H)Y]O M]H#3[A;;[1OW_P"J 7&/>OT?BA<'?V]F7]I2SA8Y3C[58;ZG['F]E"WL_:KG MMR\M^9_%?H?CW!SXX7#>5K*5D?\ 9_+5]B\7]?\ K%OK%7F]I[%^SOS\W+R_ M9Y;ZW)/",'B_]H+6-5\/?%W7M,T.'X>^(83K_P *O#FD7&G#6)K9TETS4=3U M34-4O)[S09760+'#\K\-NC+1.V6*EEG">&P>;<.X6KC)YI0E]5S+$U8S6$D^ M:%6G"C3I4HPQ4%;6;;BU*/O)58'=AUG'%>*S+AWB;%X?+XY76IO%Y=@J-2#Q M]%.G5P]7ZS6KU9RP=1\L[4X4Y.].4^67LFN__:YB(^"VHO&A$-GK_A>>;8IV MPV\>JP1ERJCA%:1!P.]>/X?32XPRCFE9R>(2;>\GAJKW?5V9[7B-1):- M"G?EPV&4816T8YA@MDME%+7I&*N[)'TO;NDMO!+$P:.2&)XW4Y5D=%9&4^A4 M@BOCZD94ZE2$ERRA*2:>Z:;37R:/K\+*,\+AIP?-"5*G*+6S3@FG\T?-/[4V M)?"?@2QC(-U??%?P5!:09^>>7SKSY8U'+$9'2OL. O=SZM4M^[H99CYS?2,( MQI7D^R1\KX@-?ZIX^E=1GB,1E]&E%Z.=66-HU%"*ZR<*525E]F$GT/>?%GA+ M0/&^@7_ACQ-I\>I:/J,82XMW+(RLC!X9[>:,A[>YBD5725&#*RCMD'Y7!XS$ MY?BJ&-P=:6'Q.&ES4YQM=.S33334HRBW&49)QE%M--,^JQ>$PV.PN(P.,HQQ M&$Q4'3JTIKW9P;3Z-.,HR49PG%QG3G&-2$HSC&2^?H_@K\5O!<:1?"[XVZLF MF6@(LO#'C[3+7Q%8)$O^ILEU?8T]E9JHV!;>T4J "I!!S];+B;)LP;EGO#5& MK7G;GQ."J3PM2_6;I7<*E1[WG42;T:MM\='A7-\MY(\/\4XG"86FY..$QU&G MCJ*6G+2A4E[.K2I05XI+VDK6M*Z;EVOPB^)GB#Q9?^+/!?CK1;+0O'W@2XL8 M=9BTJ:2;1]3L]1B>6QU73#.S2112+&=T3/)M#Q-N!D,<7!GN38+!X7+\WR?$ MU,3E.:>UC35:*5>A5HRY:E&KR^[)IWY9)*[C)>\DIS[LASK,<1CLPR+/,+2P MV<97"C5<\/*4L-BL/7BG"O1YTIQ2NE.,MFTO=DIPAK?'C_DC7Q,_[$[6O_21 MZ\_A_P#Y'^1?]C#!?^I-,];/O^2>XC_[%&:_^J_$E_X-?\DD^&7_ &(?A3_T MR65=/%?_ "4_$'_8PQ?_ *?F>9P5_P DGP__ -@='\CTJOGSZ@* "@ H * " M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H M* /"O@QX-\2>$]7^+EUK^F_8(/$_Q(U37]#?[9877V[2;B-%AN]ME=3-;;B# M^ZN!%*.Z"OIL\S#!XS+.%L-AJWM*V79="AB(\DX^SJIJ\+RC&,[6^*#E'S/F MLHR_%X7/N+<;7H\F&S/%T*N&GS0?M80H: MMX-\6:3IT/VB_P!3\-:YI]C;^9%%YUW=Z9=6]M#YL[I'%OFD1=TCJHSEF !( M\#"SC2Q>"JS?+3HXG#U)O5VA3K0G)V5V[1BW9)MVLDWH?31=GVM_D$_A;X*\.>(+/[!K.D:-'::C9_:+6Z^SW"SSN8_M%E/-!+\KJ=T4KKSUKV. M*,;A[M=.M_&?A>>15N=,NKJ\FAMX[J!?GBEFD7 12"7@A6NSA M[-L'2P^,R'.IR629@G-5%&4Y8+%0B_9XFG"*( ME@L\R11CQ#D^E*,FH0QN$G+]]@:TVTDGS2J49S:C3FZBT(_#FG^// M"&H^'/$-A/;67B'2OLU_92R6SW=A)/&L@ FM99H#>6MP$99(I)8_,@#*S+@G MY^CB*F6X^EBL%7C*K@:RG1JQC)0FZ2"%4B4Q,[;4&Z64 M\CZ_$U>$<^KRQV(Q>(X=QM>\\136'EB\-*J]93I.E^\CSOWI)C@L;3HK2-*M[2#P\U27N0E&HFX13TNJ<=C M0OAY\1_'/C?0O'GQADT+2['PA+)=^$/ 'AZ>74+:TU:1%5=9UO4I?DNKV':# M&L.]=Z1LIB".D^%7-(Q=>481FZ+,6W*"G2J>9)XP_:7L5BTZ[^#WA#6[S9Y.'KX"56M;^55:,U2;7=V7J?/1S# MC?"^QH5^'<#F4VK3Q.&S+ZO132^)TL1AW62ET4%.UG>RL=+\)_AUX@\,ZEXN M\;^.M1T_4/'?CRZL9=5CT=9ET;1M.TN%X=-T?36N )9UBCD;S)G5=Q6,88QF M27ESO-L%B,)EV3912J4LKRKVLHSK[%-KW(+X>:6R:A'KR M3*O2PF;Y5BJ\O9T,+C,+5J2LWRTZ=>$YRY8IRERQ3=HIR=K)-Z'L9 MO0JXG)\ZPM"//7Q>79A0I0NES5:^#KTJ4.:348\U2<8\TG&,;WDU%-JY\,]' MU'P]\.O NA:O;_9-5T;PEX?TS4K7SH+C[-?6.EVMM=0>?:RR0S;)HW7?%(Z- MC*L003OQ!BJ&-SW.,9A:GM<-BL9B*M*?+*/-3G5E*$N6:C*-XM.THJ2ZI,X> M%\%BR? XRE[#%83#4Z=6'-"?+.*LUS0E*$K=XR:[,[>O'/>"@ H * "@ M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ MH * "@ H * "@ H * "@ H * "@ H * .BM?"VKWEG;WMO#&T5QYA13($D58 MV"AW5P %$*%1Y=F;2+%F)9FU35V9CR2QM=%))/J31MY 95, M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * M "@ H * "@ H * "@ H * "@ H * "@ H UM,C2$2ZG.@:&PV>3&XREQ?ODV ML!!X9%*M-(/[D)7@N*7X M/D/+NFEW-S*S-/JM[Y1D8Y9X;4K=71;UWW4UH< M^L+>AP?H&Q#+_P @:P_[">K?^DNBT 9E, H * "@ H * "@ H * "@ H * " M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H M* "@"2**2:6.&)"\LKI%&B]6=V"HH]RQ HV^0&CJZEE6*,_\\X$/4G*6@;?(75OW,EK8@;?L%I%#( ?^7F;-W=9_VEFG M:+/I".PH7W!M\ADO_(&L/^PGJW_I+HM &93 * "@ H * "@ H * "@ H * " M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H M* "@ H V;/\ T"RDU$\7,_FVFG#H4RNV\O /^F<;B)#_ 'Y6(YBI?H&WD5]* MA2:_@\T9@@+W5P#P#;VD;7,RD]MT<3(/=@.IQ1L"T^13GF>XFFGD.9)Y9)G/ MJ\CEV//^TQI[?("]+_R!K#_L)ZM_Z2Z+2 S*8!0 4 % !0 4 % !0 4 % !0 M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % M !0 4 6[*T:]N8[=6$8;F64?FW5[>S)!;PH" -SN1\S,0JJ,LS$*H)(!RJUJ6'AS MU9J$4TEO=M[1BE=RD^D8IM]$=^5Y7F.T3P9=W&CA8SM:3SK MJXMYF0'/W(&/!R!7,L=32;=*I""5U*48I6[_ !77S2W/U^/@+Q31BZ>:<0\+ M9%F,5%_V=C\\I4\;>2NH\E&E7I*6WQ5DM=&STGP3\2/!GQ"MIY_"NLPWTMF= MM_ITL%"ZLHDV&-BI"N2#CKIU(58*I2DI0=K->EU?MI MMW6JNCX+B[@#BO@:M1I<195/"4<5KA\53E"O@\0K*7[G$T93I2ERM2=-RC44 M6G*"33.=\?\ QBT/X>ZWI/AZ\\.^,?$.J:Q83ZC9VWA/2+35I!;VLK13>9#+ MJEM-N7:6.R-U"C)85S2QM.&(J8;V=24Z-.G4DXQ3CRU)3A'7FOHX-.Z2UC9M MO3V^"?"W-^.,IS/.L'G>29'EV4XBEAJ]7.,96P. MHP3\$8VN[*GAZ&?MUJLF[*%-5,%3@Y/HI M3BO.Y[!X1\9>&O'6CQ:[X5U6#5=-=VA:2(21S6UPBJSVUW;3HDUIN+3C&47>$E>+6W;Y-;-;IZ,_+^)^$^(.#75,MQT(J<8R M<9TZM-MJ-6C5IN5*M3;37-3DTI)QE:47%96@?$/1=>\4^(_!?V35='\1^&?* MEGT_68+2W;4M.G.(=8T:2TO;E+W3&+1C>3&Z&9%DC1C@98>O#$0J2@G&5";I MU(2LITY+;F2;5I;Q:;35I+W90\U.&(P-2M4^ MJ8JG\>"QT*V'H2H8J-I6BE4IS4)2IU9QLWV-_?V6E6-WJ6HW,-G86%M-=WEU M.XCAM[:WC:6::5SPJ)&K$GVIUJM/#TIU:CY84U=]7Y)):N3=E&*U;:23;1\K M@\'BLPQ>&P&!H3Q6,Q=6%&A1IQ!O&=EX]T&'Q M)I>F:UIVEW<\\>G/K=K;6<^HVL#^6NIVD%O>W#K83.'\IIQ#(X0MY81E9K@W M*G3J.+INI%2Y)6YHIZI2Y7**;6NDFK-.^I]!QAPGC."LXGD68YA@<;F.'ITY MXF& JU:\,)5J1YOJM>I4H48/$4XM.K&BZM.#DH^T<47:0TOT#8QJ8&MJ/[B#3K$<&"U%U,.F+G M4-MPES9P6;K*(F^4 ME94<,DY4^?AE'$XW&XBI[RR^5/#T8-7BIU*:JSJVVK:]X;\*V=O/KNLZ)X;T]I$LK6;5M1L-'LS*(G>.TMY+R:&,R"&&1A$ASM MB8@84X[95*<&E.I&+E=I2DDVE9-I-ZVNK]KKNC\7RW)\^XDQ=>ED^5X_/L=& M,J]:&#PV(QM=0YXQE6J1H0JU%'GG&,JDE;GG%-WDK\WH'B'X7:EK]W-X7U_P M+J'B;6((UO6T+6-!O-9U&WT]99(S.MAT5#D] MY^TFH6WTASR2]4KOJ^[U][.'LKJ2E0CF&"S&A@<+5Q M#A"7LWB*4:-*55QC%)./-+97D[^;^)?^3D_AI_V(WBS^5Q7)AO\ D;YI_P!@ M&%_]2YGWW#?_ "8;Q$_['F3?^E4SZ"FFAMHGFN)8H((E+R2S2)%%&B\EGD/+(N.%Q#2Y)X&XK4:&/@[MX#$:+#YIAK)N%7#3474<4W*G%-QG*E3B>7K MXGN/VD;W2?#&F6FI:+X"TB*QU3XG-<1S6EU>:RCEX/ D$K!&>)+B%Y+F9%&4 M1"#&RHLKA&..KQQ#M++\,XRHIV:Q%5Q4E.23:<**DE:[3G=I-2IU(_HSXG)M*;DOWD9N M5/ZQM[>"SMX+2UABMK6UABM[>WA18X;>"!%CBABC0!8XTC5550 % '2O0;; M;;=V]6S^:<1B*^+Q%;%8JM.OB<1.=6K5J29,Y8A M1M50,!$1?X8T0*JCL% [4]OD'X$FGVPN[VVMF)6.25?.8?\ +.!/GGD^B0K( MW_ :-@0V]N3=W=S=$;?/FDD5>@1&8[(P!T"IM4#T44EI\@_ JTP-.7_D#6'_ M &$]6_\ 271:0&93 * "@ H ^9_%%_'\,?CE8^--8/V7P;\0O#MOX5U+5F7; M::1XDTR=9=-FU*;I!;S6J)"LCX WS.Q"0,1Y^&E'"XW&X>I[DVL&J6-I MJ=HDQB>..Z@2YCD02>3-(HD49VRL <,<]DZ5.;3J4U*4+I-K5)VNO*_*KKR7 M8_&,JSO/^&<77KY+FF-R+'2A+#UIX2O6PE;DYXRE1J.E*$^55*<7*$M.:";5 MXJWSO)H7@WP[^T7\/M-\)Z3X>T:1/"7BV75[+0K.PL7222W LY-0@L40J[1K M)Y9E4$J#MXKCPG*LQS&%-_NH8.@K1?NQJ?6KS6FBGRNFY+>SA?2Q^Z8?.>*L M\\#..\=Q+F699I3EFV30P5?,*V(KQ<8UOW\<-4KRDFHR/AUX=\3V+:AI$_@SQ'<2VJW=W9%I;22>:!O/L9X95VR*#@. <8(( MXK&G0IULVS%5%?V>"PLHZM6?UFK'I_=E)6??ND:^&O$^=<'^#G'V>#]+T%/$'PY\-1G M7O#EY!K$FA:A?:IJUAXGT^S82WNBSP:C>3[9)858Q^5L+D&(D&17C>)HK".G MBH4_:T*#?MZ3UYJ;5G.+^)2I[V5_="6/P^'PF#Q&58BLN2ACH5,-0HWC3FTJGM.90B_:I/V;A/Z$^&'B/POXH\ M$Z+JO@^SM-+TAK?[/_8UI!!:KHM[!A;S2Y;6W1$AF@F+#A%#JR2C*R*3ZJ<7 M&$J5RZ(DGGUW+%UO[/I2<*:BI8JHG;V M=)VM3B_^?E6Z5E9Q@]X.<)KZ7PTX4RNK1S#CWC"#CP7PK*,I4792S?,M)87* MZ"E\:E)PGB;74:349$4HX#$4WSN<;RE.<*=.?U587UGJ=E::CIUS#>6%_;0W=E=V[B2"YMKB-98)X9 M%X>-XV5@1V->BXN#<6N5QW1_.&-P6+RS&8K+\=AYX3&X&K.C7HU(N-2E5I2< M)PG%[2C)-,M4CE"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H M * "@ H 4#L/H /TXH V-0/V*"+24.)(V%QJ3#C-Z5(2V./X;6)BG_762;MB MDOR#;Y&-3 UK#_1[/4KWE66%-/@/3]]?;A+S[6,-VIQT\Q<]>5^@;>5C)I@% M &G+_P @:P_[">K?^DNBT@,RF 4 % !0!F:QHVD^(--NM'UO3[35-,O(_*NK M&]A2>WF4$,NY'!PRL RL,,K*&4@@$95:-*O#V=6"E%--+5--;.+5G&2Z2BTU MT9WY7FN99)C\/F>48VMEV8827/1KT)RIU*;M9VE%K22;C*+O&46XR3BVCQ8? ML\>%K5HX=%\7?$[PUI,9./#^A>.+^VT8HQR8O(N(9YDCY(PDZGD\USK!02<7 M6JRA:RBY*R2TMI%/MNWLC]:_XCGQ'7C*IFW#/"F?YC)+_A1S'(.\WXDX?R#A_.,- M@\4^&HRI8/,73K+,_JKT6$K5_K'L:N'II05-2P_M(*$>6IK/GE\,?#_1O#&N M>)?$L5UJFK^(/%5TD^HZMK4UI<74-K"H6UTC3_L=E:QV>DP!1LA"%CA?,=_+ M38\/0AA:3I4[RSIPYY\W8W=I;7M MK<6-Y!%-XV92I&"":JK2IUJ:0E['-.G%TJ5*ESRG[**BISMSM+1K?\ I+HM(#,I@% !0 4 % !0 4 % !0 4 % M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!- M;P2W,\5M NZ6:18HU'&68A1D]@.I)X !)Z4;>5@+NISQEXK*U;=9V"F&)QPM MQ*3FYN_^VLH^7N(TB7^&DM V\K&93 L6MN]W9$0LMO,!A9[:51)!, M!VW1LN1_"VY3RIH7Y!M\BG3 UM+_ '"WU]T-G9R)#V_TJ]_T2''^TB2S3#_K MA2V!:?(R:8!0 4 :K"EM\@7W6%O[O[95"B MI#:P]1!;1#9#%QW"C+'^)F9CRQH6GR N0_\ $PT]K7K=Z:LEQ:?WIK(DR7=L M/4PL3<(/[IN/44;!^AC4P-:;_1M)LX.CWT\M_(.A\FWWV=ID?]=!?GZ./J5^ M@;&33 * "@#3E_Y UA_V$]6_])=%I 9E, H * "@ H * "@ H * "@ H * " M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H WKF&72] M+MX3&R3:LBW,\A! %I&P:WM W3H!MP<TC')BE9Q'-9G_:A MG.P9Y*&-OXJ6WR ;J\BM?211,&ALUCL8&' :.S18/,'_ %T='D/O(:%H&WR, MRF 4 % &G+_R!K#_ +">K?\ I+HM(#,I@% !0 4 % !0 4 % !0 4 % !0 4 M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 :>F01,\MW= M+NL[!!-.A.!/(3MMK,'UFE&#CD1I*P^Y2V!:?(EAU,RR7$>I[Y[6]E:6<+CS M+:X;A;NT!P$D08'E@JKH-AP I4V^0%.\LY+*41LRR1NBRV]Q'DQ7$#?0+3Y'+L&5F5@5920RL"&# X(8'D$'KFF&WE8;0 4 % &G+_R! MK#_L)ZM_Z2Z+2 S*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % !0 4 % !0 4 % !0 4 .569E1 69B%55&26)PH '4DX&*-O MD!K:DPM(X=)B8$6C&6]92"LFHNNV0 CJENF(5[;EE8?ZRDM V^1CTP-6RNH3 M$=.OB19.^^*< M)I\Y&WSXE'+1,,"6(??"@C#HII;?(/T*=U:364QAE ! #H MZ$-%-$XS'-"XXDB=>0P^G!! ?Z!M\B\";71UP2LNH7F[C@BVT]<*0?1[JX;I MWM/S7X6#874 +R&+5HP-TS"#4%&!LOU7=YV.RW,2F7/_ #T6<RW[==/+ MR(: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * -O38GL[6XUHQN1 M;NMK9,%)07\JDB=FP0!;QY<9ZR-".F<+;0%I\C%).??KSUS3V\K )0 4 :]I M<17,*Z;?-MC7/V"Z(+-93.V?+?:"S64C$[T )1CYB#.Y9%M\@_076T:VNX[! M@5&FVMO:!2, R;/M%RZC^Z]U/.P/<,#FA!M\B'3;B**62VNB197J"WN2.3%E M@T-TH_OPRA7]U#KTSCTUWM;O3 M8))KS29 \"ZE'\TYN@V,7#_9W4^7( P5 T612J?;EO34.22_Y]22Y'*W^/5M M>\I:2TU""^&&TY3YHO\ Y^1=I1A?I[J<4OAE%WO?0S&T-(K07-[>M:S2V;7T M49M2\+*W,,#7)F3%W*#N6-(Y,#EBO8E:FW!:NFXQ:\W:ZC_-R)WEM&^E^HXM MSM+92=DDN\M_=T6WO7=DHKF5.VGM%+E7G'FU?:'NK MW_-^[HQUCIRV.H));WTZ[='FU6"<6L*2(GDS92:"629%#1J0,%C^\4\$4I-J MGB8VLX*,6KZ-34/==M4TYI.VUG9CBDYX?6RG-Z_RN$I*Z[KW&U>WFBI:Z%'* MMHMS>M;W%[;37D4$=J+@):0I+)YUQ(;F(1;UA?:JJ_;=MS3G[BJ6U="'-);) M:+EC?7WM8WTTOU>C4?>TG;2R3OZV?34?::!!^R28 MD_=;V49J'SE;EMM=ZZIV2L]=KQVFAV]Q9P73W[P^;J']FB);,2.\YV[#;G[4 MHF0AP6+^5M ;J=H<2NZ45O5BY)=K.SYNT5K=J[V]W5VT5H[6=^96()-'"6]S*EPSRV^JKI8B$&(YG;S=LD4HF+9Q%RIC'WQAC2IOG^ MK6T5>_\ V[;E;?FO>6NG730Z]%=LL1V8TI?$\2R^=]ELX;'S?+$>Y[JYMPXV M>8V,!'7[Q^[GCI4N7-12M;FKQBO2FZDK_/E3^817+5CV5&<_1SA%)?+VEO4B M\+RSP3ZC+#,\(ATF\E.)C#&9 @B@,C%E7Y9)05+<*>>,9%RO[&HD[1+=N85=$W*07?!&8QD9+VC4?2G&$M-;\S2<5;[<6TFE=7TO=#2UIQ MZSDXKILKJ6MO==G9NVU]F,&@))';74-]FPEMKNZFN)K8Q2V\=E*L4P^SK/)Y MK,[H(P)!N+8.W!P-\G-S:*,8-6U;]HVHQMHE*Z=];)*]VA)7LH[\THOHERQ4 MG*^_*HN][7V5KLDA\/0S26_EW[K;W=A;1THPGIK>,[)6V?,K_#;6VX+7V5O^7DY4_-2AKWLTUUNO-"+9:5 M%I%_="ZN)]US:VMO,=/C5DD$4EPZ!9+W*!BJJSJQ(4#"MO("G=1I)*SE*3WW M4(\MFULKS3ZW:6BM<<$N:=WI&"OY.4UJKVNTH-*_+HWML^9JA!0 4 % !0 4 M % !0 4 % !0 4 6+6VDN[B&UA \R5PB[CM51U9W8\+&JAF9CP%4GM2V^0?@ M:5QJDEO*5.T MD,R$I-&?[R,P]Z/T#;Y%6F!J:.B_;HYI%#0V*27\JG[I6T0S)&?:298HOK(* M6P+3Y%B&X74T%E?2JMRK.;&_E( 5G)8V=VY_Y=7-P59&7@@@TPV\K&K)_Q,-.6?K=Z6D<%QV:;3RPCMI\=V M@D80,?[CP?W6-+8/T,:F 4 :T::.V2S M6\,3FZ^S)D+%\TIB!"G;YBQ"3;QNY.6]92>W,U*275JUF^JV3:32;2N@C[J2 MZ134;_93W2Z=7:][7=K,)=9NI3>$QP*;RTM[%]JR#R;>V\G8L ,IV[O(3=NW M9R<8S2:OS+^:I[5_XDY-+T7-HM]%KH$?<]G;_EU3=.*\FK-_XM]=M7H3#79U ME,OV2R).G#3'4K=%'ME2-%ROVKY7"Q@94J#N;(.>"2O[7I[62F_*2=U;TLM' M=:+SN+W522_YO#K5S;R6$BQ6Q_LV.XCMXRDHC/VEI6D=U293OS*<%"@&Q M>..1J_/?7GIQIO\ PQ5M.MVKW?F]@V45MRS=1?XKQ:7HN5)+LNHV+5YX/L(B M@ME33[N6]@BVS%#-*T;8EW3EG5?*0+A@<#DDG---II[N,'37H^:[TMK[WIHM M--4U[LH_"I2C-^L4DEK?2RU]7KM:6#7;BV$@BMK,;KS[?$72>3[/R32_POEO%^344KJTK77-J.7O.;>G/:_JN:TO5 M.3=G>-[>[96)6\17+/*SV>G,)+Q=05&AG,<-XH*F>-?M/+,#\RR&13@<<4HK MD]G;>E?E?5)VO'TTO_,G=IIZA)\W-?:45%KORWY7ZJ[7:VC36A#-K<\XU%7M M;)1J(_:#\VZ5V_>>8,XP % "Y4H0AJE3DY1[JZ4;=K65M MKZMMMNY7,^9R[Q4&O).Z\[W2Z_92M;0J6FH/907<"06[B\B\B5Y//\P1!TD" MQF.=%7YT4\J<]#Q3EK#DV2E&6F]XWM]U_P B8^[)2ZQ4HI=+25G^!=AU^\@6 MT'E6LKV<,MJDLR2M))9R@JUG.5F59( K$+\H91]UA3>KG=?'%1DOYK;-]I*R MU5F[*]P7NJ*3MR2YXO\ E?6WD];IWW=K:6O:7> QZM=FTM$@M-):WCM$298, MW=S!"5=_/\]RP9R6,Q;T8 !2TI2^TY5*4=>B3E/2UK6Y;^;U=PC_$@E[JA& MK/3NHR8$XEWF0!_,\W?N& M=U%K\_-[W,XMWZ3FM;^\K2O>]^9;^BVL,?6[MG MD(CMT1K!]-B@1'6*UM9""PMU\TL)#@Y>1I"=[9R<8&KJ=W=S<6WI?W&G&*MH MHJR5DMEI;4:?+R67*J?-9>M=?X5) M+[N9[Z7L[710H * "@ H * "@ H * "@ H * "@#9C_XEVG&7[MYJB-% .C0 M:RTN\,J-%/>72:>$D4I*D5ILN[Q61L,#YQL!@CL0:/T#8QJ8&Y"Z MZM%':3,%U&!$BL+AR%6ZC3Y4L+ASP)0,"&0X_P">;'!0HM@_0H6EQ)IUX'>, MGRVDAN;:0%?,B8-#]#]VR?NM[+;[@6M[:VWM_7D5Z "@ H L M6]I=7;,EK;7%RR+N9;>&29D4'&YEC4E5SQDT;)O9+=]/ZT#JEUZ((+2[N7:* MVM;B>1 2\<$,DKH%.TEDC4E0#QR*.E_LKKT\M0V?+L^W73?3R("I0E6!5E)5 ME(*E2IP00>A!XQ27EMT!IK2UFNA/;VEU=L4M;:XN74;F2WADF95Z9*QJ2!GO M3M97V2Z]!;66W9!%:W4TQMX;:>6==P,$4,CS#9][,2*6&WOQQ0M5=:I=5L-^ MZ[/W7M9Z?@(MM=KA6*&W6*0S!@<%3$%W!@>,8S0M5=:I=5M8'[NC] MWR>GF+!:75S(T5M:W$\J EHH(9)9$"G!+)&I*@'CD4+:Z^%=>GEJ#T?*]&NG M73?3R(65D8HRE64E65@5964X*E3R"",8-)-65MN@--:6LUT&TP"@ H * "@ MH * "@ H * "@ H * "@ H O:?:K=7&)6,=K C7%Y*.L5M%@R%<_\M&)6-!W M>1!WI; ,O;IKVYDG*B-3M2*%?N001J(X($_V4B55]\9/)-"T^0?H5*8!0 4 M% '4W]^B"STS4(?ML=I9P*\PD9+ZWN)U^T2^3<-N!\I98H3%(KI_HP "GYJ2 M5O(-M.QERZ86C:XTZ47]L@W.JILO+51Q_I-IEF51_P ](S)'ZL#P#;RL'Z&5 MT]L?AC%,-O*QNKC6HPAP-7@0[&/75(D'RQMZZ@BC"GDS*,$^8H\Q;>B#]".U M!O;*33F'^E6?FW5AD89D W7MGZY*KYR+_>BD YDHV#\+&-3 TY?^0-8?]A/5 MO_271:0&93 * "@ H ZQ((Y--\-6,BR%+^_O)9%B=8I#OGALXV5WB<+@(3RC M<#WS3Y5*O"#T]G16O;GE.;?G9)::>I*;A1K276HK+_KW!)KRUE9=GT>Q7ETN MUM[2ZN2D\B#7!IUF?-6-Y+>(3&4[O+*^8=L0W[" <_+VJ:?O_5$_=E73D[?R M^Y&-KWM[S?K:URYI0>)UM&@HI-_S7;DG:WV5=+SN6K_0]/@.IPV7LK67/5=-/O92;DNW+9+K>]U: MZ0.T%+FNN6E[1I?9^#1][\S:M:VF[N5-4TS3=/CN8%FN7O[66&+<);>6WF/S M+ZF[61!H;PO=6UK<7-U"C7EO)!#!&OE37(;;&9YO,WPJK; M"L4QPS8"]3K"]X\MG.',XIZ16B?2][VLUI=)+F2N93LHRO[L&K2:WLNVVUV[ MZV?V9.R-K5?M2VUI$A5;S5-;U"6Z^S$JKW-K=);V\:MP2B,S,H..6W$9YK.A M;VF$C&ZC"G&:OWJ2;E)K:ZC'E=ME=;&E3W8XJ4NDE#3^2%--1^;=^[:UV,3Q M&\;ZYJ1BQL%P5)4 R(BI*>/657.>_7O44O@TT3E)K_"Y-Q_"UAS33BGO&$$ M_50BG^.Y#IR7$H*_:'M=/@EBN;N;<5CC,>?+("\RW)&X11C)+$XP-Q&T9*#A M.6JIOW4MW+3W8KNTE=[1CJVD9M-J4(VO)6=]E%7LY?W4WMU=DDY6-[4KIYM, MOKZ*-H)=5UOR94QME%M;6RO!!)CNS,KMC&X\\C%9J,HO#4EO+VE1I?\ /SVG M*E_V[=\M]KWLF:77[Z?2,:5--[\O(VY>7,HJ_DK7:+HD:+Q5$!(ZFUL87OMK MLH>>RTPR2&7:?WA5U .[/.:&URXZU_\ E\EY&)I\D5YIXTQ;O['>S:K'<$F*Y?[6AC$<4:&VB<^;',695DV M+E\[@1D:1C[V'Y=%2YM.SO%J:O9*T59NZLEV%*5O;RDOCY7?R7->+2N]6T]$ M[M6ML0>)GB?7+_R2&59(XF+:7*I2FTO)R;7RZK MR+DN54XMWE"$%)]VDOR5D_0P:T)"@ H * "@ H * "@ H * "@ H * "@ H MZB%[?3HH])N@%_M.-'U24C+V?F /IR+W4P-LN)0.6\TQD9CI?H&VASUQ;RVD M\MM,NV6"1HW .1E3C*L.&4C!!'!!!'!IAM\B"@ H * +^EP)<7UO'+Q C&>X MST%M;(UQP)XI[?(/P M&12RV\B2PR/#+&=R21,R.A'&5=2"#CT- ;?(U?M=E?<:C']FN.@U&TC4!CZW MEFNU9>>LD7EOW(D/%+;Y 5;FPN;()."LMLS#R+VU%-^L W?:X%'_+ZFT&6,?ZP9D4;@X)L M'Z%+4X8R8;^V4):WX9Q&O"VMTA47=H/14=E=/^F4T??-"T^0"2_\@:P_[">K M?^DNBT 9E, H * %7 (W E01N52%) /(#%2%..^#CT-"LFK[+IM_G;[F)WMI MH^G_ VGYHU+K59)9[*2U0V<>F11162!Q*\7E.9?,DD,:K)*TK%F.Q0>!MP* M$VIRG?WI66VBBH\JC9WT2[WO=C:7(J=K1C=[Z\TG=NZM;I:VUD.DUS5)(_)> MX3RA*DRQ"UM$C22,AE,2) !$NY02J!58Y+ DG*7NN#6C@_=?;:WR5E9;*RL@ M>JDGM-6DN^]WZOF=Y?$[[D!U2^*W:F96%[.+FYW0V[,\ZERLJL8BT+@NY!C* M8W<4)K:2T3?5I:@FTK=DE MW=ELKO6RZ*XZ#5K^UCCB@EC00AUAD^S6K7$ JOWL[J^BU\EV0EMJVH6<9B@N-J;WE4M%#+)#+(N MR26"66-GMI&7@M$R$^O%)JZ4=E%.*MI[KU<;JSY7_+MY:@M&WU;3=]=5LVG= M771[^8+J#IITVGA2RSW*7,CNX8!HUPIB38"DAR=[EVW# 7!+#5_9K94[V]6 MFK>4;=.ZO?H"?*YO=R23]$U+YNZT?1-JS;NEAU:\M[=+1/LK6\;M(D<^GZ?< MXD;[S[KBU=B^ !DDG Z "FWK%[.*LNEEOI;SU]=1+W;VT4FFUZ*R^Y;?/NQ MT6LZE"\TB7 +SSBYD\R"VE47"YVSQ)+"RP2J&(#Q!"!@ @ 825HJ*T4;VU=U M?27O?$K]==>H^M]M%&UM+1^%..S4;:::$5MJ=Y9R32PR)YLZR+-)-;VUS(ZR MC$H+W,,APXSNP>7X5:SMN_5[ M^5DTGU3!:.]D[;)K16\M%YZWU,XDDDDDDG))Y))ZDGUH2MHM$MD#?WB4P"@ MH * "@ H * "@ H * "@ H * "@#5TR*-#+J%R@:VL C+&WW;F\WR U9O]/T]+D?\ M?>FI%;W0_BEL"0%)D]F4X/(P1FE;\ V^1HQ&QNI$EM91HVH(RNBF1Q8/(IR&AN&)DL'W M#A9"\?\ TT0#%&WR#\+&XEFU['=661(HE9Y)'6.-%&6=W(5%4#JQ8@ >]&WE8#H[ZWM%BM].BU?3 MH8[/<;A635&:74'P+F1F@TV2-U3:L,95V&R+<"#(PI+3R#;Y&9]@M?\ H-:9 M_P!^M9_^5- %RPCMK*Y27^V-+DCPT5Q"8M9"S6TJF.>%O^)3QNC) /\ "<,. M5%'Z!M\AMWI%M;3;1K-@L,BK/:M)%JI=[63)AD8PZ8Z!RO#!6.UE93@J0#] MV^15^P6O_0:TS_OUK/\ \J: #[!:_P#0:TS_ +]:S_\ *F@#4O;*VAM=/L?[ M7T^(PQ->3!HM5^>:_"21N!'IC87["EGC?M8'=E0",B_(-OD9?V"U_P"@UIG_ M 'ZUG_Y4T 'V"U_Z#6F?]^M9_P#E30 ?8+7_ *#6F?\ ?K6?_E30 ?8+7_H- M:9_WZUG_ .5- !]@M?\ H-:9_P!^M9_^5- &WI+S02P6UMJVG7RK)NALV@UR M1D<_>>V9-)\RV$U0@H * "@ H * "@ H * "@ H M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H V;'_0+234V^6=R]IIJ MG@B4J!;JQ$MU8=S) M !OO;,=R553<(/5)@.7%+;R#]#&I@6["V^V7EM:YVB::-';^Y'N!ED/LD89C M[+2V^0!?W/VN\N;D#:DLSM&G3RX0=L,8]DB5%'^[0M/D&WR*E, H * "C;RL M!KIIBVR++JLK6:$!H[5%#ZA.I&05@) MXR/^6DQ7@Y57Z4OT#;RL=-ITD5I% MYKP+8V@MVNA:(?,N'M48*MWJ=PZ@SF67;';6Q58GD=9#'L3]XOT&M/*QAZEJ M%S>V,%Y)(ZR3ZMJS%5=@%5;31%CC!SDJB *,]A[TUI\A'/4P"@ H * "@ H M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * +5G:O>W,5 MM&0I6:0]HXXE9V/HII;?(/P)=1NDN9PMN"EG:H+:SC/!$$9)\ MQA_SUE=GE?\ VI3V H6@;?(H4P"@ H E@FEM9HIX6*2P2)+$PYVNC!E.#P>1 MT/!Z&@-OD7]3AB#17UJH2SOU:6-!R+>="!=6GTBD(*9ZQ2Q$\DTEI\@V':=_ MH]MJ-]C!BMOL<#=,7&H;H3@^HLDO3QW Z=:/PL"T^1DTP"@ H T;739IX_M$ MK1V=DIPUYQ^72HF65>#J5TJ M&Z]";6$%H[)3V8&27TD&=H-OET#;Y"P1):QKJFH#SY)&WV-I,2QO) 3NNKK) MW&S1QT/^N;*@[5<@_0-OD2:I/-!&+*5V:\N'2]U9SPWGLN;6S..BV\+9*# 6 M29EQ^Y7 ORV#8J2_\@:P_P"PGJW_ *2Z+0!F4P"@ H * "@ H * "@ H * " M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * -G_ )!VG8^[>:H@)[-! MIBME1ZJUU*F?^N4(ZK-2_0-C&I@% !0 4 % &OIC+<)+I4K!4NRKVCL0%@U" M,$0,2?NQS*3 Y_VT8_ZL4MOD"T%O4:ST^QLG4QS2O/?W"GAEW.;2VC=>S*EO M*X'7%S1^@;>1CTP+5K97-XY2WB+!!NED)6.&!/[\\SD)"G'WG8#MUHV#]"_N MT[3ON!-4O%_C<.NFPL/[D9VO>L/5_+CS_#(*7X!L9US=W%Y)YMS*TK@!5W8" MHB_=CBC4!8HU[(BJH["GM\@_0O6=K##"-1OUW6RLZ6MMDJ]_<1@93(Y2UC8J M99 0?X$^8Y1?@&WR+%M,\LUQK=]MD6T,8@B*A8I;PJ5LK6.,846\*IYC(HP( MX G'F"C;0/T,1W>5WDD8M)([.[LGN11M\@_ Z+6D_M6X-_8K+<,;G^SIHUW2R&2$, MEE.JJ"=MS:Q X&?WD,OJ,I:>5@*'V.SL.=2D\ZX7IIMI(I9&':\NQN2W Q@Q MQ^9)V;RSR#] V^15NM1GN46 !+:T0YCL[93%;H1P&9G!!DDY$:'/+,BLM@V^1'--UMH1MBA0MMAMH$S\D:YP/4DL2222;?(";4Y8T,6G6S!K:PW(9%^ M[<*=R:%]P;?(RJ8&G+_ ,@:P_[">K?^DNBT@,RF 4 % M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %&WE8 M#K+/_0-0T32E^68ZIIMUJ1'!%P;B/R+-B.UO$Y+#M+-(#R@I?H&UO(Y.F 4 M% !0 4 % '3Z3I[V0DU74";2WM[61X%(5KIY+E3;6\L-LS*VU7E\Q'F7*M;W;JWF7\DF&WR*] &C8 MV23![JZ=H-/MF43RJ!YCNP)2UME;A[F0*<#HJ@NV%7E; ONL1WMX]Y(GR+#! M @AM;9,F.WA4DA%)Y=RQ+,[?,S,2?0/;Y!^A-L04_ZP4O(%I\ANCN\FN:7)(S,[ZK9 M.[L269VNXF9F)ZL222:-EVL",JF 4 % !0!?M=.GN4:;*6]I&<27ERQCMT(_ MA5L%II<#B.)7<]EI;!^%BU]LL[#Y=-C\^X7KJ5W&I9".]G:'^SDX_=KW' MM/*P;&-3 V6_XF&G!^MYI481Q_%-II8+&WNUM*^P_P#3.5.T5+8/T*EC9?:V MD>23R+2V4275RPR(DSA41BY*10Q_9[*WRMK M:@YV XWRRL /-N9" 7<^RC"JH E8/T([&T:]N8[<,(U;<\LKL5M%D1AL?\ +1B6D<]WD<]Z M-@_0HTP"@#3E_P"0-8?]A/5O_271:0&93 * "@ H * "@ H * "@ H * "@ MH * "@ H * "@ H * "@ H * "@ H EAADGEB@A0O+*Z11(.K.Y"J!^)%&WR M OZG-$K0V%JP:UL T:R+PMSCNJHGI'#$.QI+0-OD)HG_ "&=)_[" M=A_Z514 C,I@% %BVM+B\D\JUA>5P"S;+T1"RZ;"PZ;Y!M>]8>B>7'_M2"E^ ;%"ZO+F\=6N)"P0;8HP% MCA@3_GG!"@"0IP/E10._6GL'Z%=$9V6-%+.S*B*.I9B%50/4D@4;?(#2UAE^ MVM;QMNBL(XK"(CH?LB"*5QCM)<":3/\ TTI+0-OD9=,#6T99A>I-&46"W!>] MDFR+=+-AY5PL^.JR1NT8099BX5!N(I; M/D3ZTRQ&VM;,;-*$2W5E@DM<><, M27%RV!ONED5X6'2/R2B\ EA?D&WR,*F!LO\ \2[3EA'RWFJ(DL_9H=.5@UO% MQT-Q(HE8?W(X>TAI?H&QC4P"@ H TY?^0-8?]A/5O_271:0&93 * "@ H * M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H W].:'3+8ZC5(D)4QWEY')L;RW4-Y,;%6&YI#C]W2\NP+0KMIBSHTVE2F\C4 M;GM64)J%NH&26MP3]HC4=98"XP"65.E&WD'Z$>B\:SI/;&IV'MC%U%1T!:>5 MC.1&=E2-69V(540%F+'@!549)SV%,#7^P6]C\VJRL)1TTVU9#=\<@74I#)8K M[$22_P#3, [@O3H&WR*]SJ4T\?V:)8[.R4@K9VP9(R5X5YW8E[J4#^.5F(R= MNT<46L'Z&=3 * -71P$NFNV'R:;!+?\ 3($L "V@.>,&]>V4^Q-+8%I\C+)) M))))))))R23R22>^:>WE8"S9VDM[.L$.U2%9Y)'.R*"&,;I)IG_@B11DGZ MD@$V^0?H6KR[B$2V%AN6RC*M)(PV27]P@(-S,O54&6$41)$:G)^=F)5K?(-O MD2V7^G69AE;>WB4R3SM[)$K''-E>-F1T(9'0E61EY!5E(*D'N*8;>5CMM' M5KJ\TRZUB*."3[;:/97Y;[/>WTJW$?E(]LL;?;HFYGA_&U/I2_0-D4+:VFNY MDM[=-\C9P,A555!9G=V($<:J"S,Q 4 DD 4]OD!H7=S#;0G3;!]T(<-=W8!5 MK^5.@4$ K91L#Y:'ECF1N2%1?H&QD4P)(GDBECDA9EECD1XF3[RR*P*%":5>'^)0[:;,PZ;D&Z2R&9.TD$T9*31_[2,P]Z?Z!M\BK0 4 ;>H M02O>6FDV\;/+9P06*Q+U-VY:>[&,X!%W/,N3CY8QG '"0?A8;*,?--M/[JV4] M%,LF%+'[J"1S\L9(6P+\BQ)5BMH%_NPP1@(GN0,GJQ)YHM8/T* M=,#3T3_D,Z3_ -A.P_\ 2J*D",RF 4 7[749[5#!B.XM&.Z2SN5,ENQ'&Y0" M&@EP?]9$T;_[6.*7Z!M\BU]BM+[G3)##<'KIMW(HXGMV1ED(M$,Y@,9&[?(R+$%QDF4 =:-D"T^1/ M=W'V#[1!'(LNIW;.=2O$(80>:2TMC;./XB6(FD!Y(,:_*&,A^@;&!3 * )K> M"6ZGBMH%W2S2+'&O3+,<#)/"J.I)X !)X%&WR NZG/$SQ6EJVZSL$,$#C($\ MA.;F\(]9I1D9Y$:1+_!26@;?(S*8&S>?Z=9Q:DO-Q!Y=IJ*]68JNVTO2!VDB M3RG)_P"6D(8Y,U):?(/T,:F 4 % &G+_ ,@:P_[">K?^DNBT@,RF 4 % !0 M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 H!) )). !R23P .] M &W?3/86ZZ-!(R;?WFJ%&($UZP&;9RI^:*V4+'M^Z9!*W/RD)!MY6,.F 4 % M &GHG_(9TG_L)V'_ *514@1F4P"@ H 4 DA5!)) 50,DD\ #OF@#O$O&TC2 MC]ODDN;Z>0Z:WEM$EWIUJ8A+<6\5ZT;M]HCS:EHVW+&954;7#XGTTL/8Y>73 M-\;W&FR_;[= 7D14V7ML@ZFYM,L=BCK+$9(\=64\![>5A?H95, H V8/^)=I M[W1^6[OUDMK,=&AM!F.\NAZ&0YMT/IY_H*7Z!L8U, H OZ==):3_ +Y2]K.C M6UY$.KVTA&XK_P!-8V59$/9XE-+\+ M"*\M6LKF2W9@P4AHI5^Y-"ZAX9X_] MAXF5A_O>HIK\@V^15H * -.7_D#6'_83U;_TET6D!F4P"@ H * "@ H * "@ M H * "@ H * "@ H * "@ H * "@ H * -C35%G%+JT@&;=O)L$8 B34&7&I>78%I\C())))))))))R23R22>^:>WE8!* "@ H T]$ M_P"0SI/_ &$[#_TJBI C,I@% !0!NJ!HL2R. =6FC5[=" ?[,B<96>53_P O MSI@QH1F)2'.'*A5^@;>1#JC&)+"RW%FMK59YR0;6\C,BED@D26&1X98SN22-F1T8="K*05/T-,-OD:OVRSOOEU*+R+@]- M1M(U!8] ;VS7:DP]9(O+D[L)":6WR#]!T6B3&:(O(C:<0\LFI6Y\VV2WA4R3 M-NP#'.(U($,BHY8JNWYADO;RL%BA?W7VRY:54\J%0L-M"#D06T0"0Q#W" %C M_$Q9NK&A:?(/PL4Z8!0 4 ;*_P#$PTXQ];S2D9XL\M-II8M+'[M:R,9 /^>< MLG18@*6P?A8QJ8!0!IR_\@:P_P"PGJW_ *2Z+2 S*8!0 4 % !0 4 % !0 4 M % !0 4 % !0 4 % !0 4 % !0 4 3VUO+=3PVT"[I9I%C0$X +'&6;HJ@&)L;CB1OD"B1?H&Q4L(OMNHP+<.S+),9KJ5B6?R8PT]W*Q)R MS"%)6))[4;>5@_0@N[A[NZN+I^&GFDE(Z!=[%@H Z*H( Z "GM\@*U !0!T M N9M$M(K>$JMW>B.ZO5D1)46U*G[)9RQ2*RMYB.9Y 1TDA'!4BE^@;$&W3M0 M_P!64TJ\/_+.1F.FS,?^>% M\!E# %70_=>-U)66,]G0LI[&G^@;?(KT % %BTN9+*XAN8L;X7#!6&4=<%7C M=?XHW0LC#NK$=Z/P#;Y%G4K:."9);;/V*[C%Q:$G<41B5>W=O^>L,JO$WKL# M8PXI+[K!L9U,#3E_Y UA_P!A/5O_ $ET6D!F4P"@ H * "@ H * "@ H * " M@ H * "@ H * "@ H * "@ H V8?^)?I[7/W;O4DDM[4'AH;$$QW=R/0S,#; MH?[JW'J*7Z!L8U, H * "@ H T]$_P"0SI/_ &$[#_TJBI C,I@;-M!#8P)J M%[&LCR*QTVR?D3,K;?M=RO\ SYHP("'!E9PU*\Y5FCCTV _[=V6>X(^EI;S(?^O@> MHROPL"T,FF 4 :>F01%Y;RY4-9V"K-*C<"XF)(MK/W\V0?-CD1I*W\-+8%I\ MBE//+J/10DO\ TS/6C8/T,AE:-F1U9'4E61@5964X*LIP00>,&F&WE8;0!LZ? M_IMO)I+?ZUF:XTUCU6[50)+4>BW,2!0/^>L4/J:6WR!?=8Q\8XZ8XQTQCVI@ M:4O_ "!K#_L)ZM_Z2Z+2 S*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0!=T^T%W<"-V,5O&CSW4P&?)M81NF< ]7VX51_$[JO>EM\@-:2Y_M MJ*XMQ&(YK0-/I,*]K*&-5FTY>[,MO$DR=RT4V,M-1L'Z'.4P"@ H * "@#3T M3_D,Z3_V$[#_ -*HJ0(?9VT-O"-2OEW0!L6=H25;4)D/S9QRMG&0/,.(T M.XDH?H&Q0N;F:[F>>=MTCD=@JHJ@*D<:#B.-% 554 * !@4]OD'X$% &M?? MZ/9:99=&,3ZC./22]*B 'Z64%LX]/.;'4DI:?(-OD9-,!RJS,J("S,0JJHR2 MQ.% ZDG Q1M\@-74F6U2+28B"+1B]XZG(FU%@%F (ZQP*! O;*2,.)*2#;Y M&13 * "@!1QTXQTQQC'2@#674DN%6'58FNU4!([M&$>H0*.% F((NHU_YYSA MN.$>/.:5K;:!M\ADVF,(FN;&5;^S0;GDB4K/;@\?Z7:DEX,'C>-\9/W9#1MY M6#;Y&:K-&RNA*LC!E920RLIRI!'0@@'-,-OD:NI*MRD.JQ *MVQ2\11A8-10 M S# ^['.I$Z=OGD0?ZHTEIIV#\".7_D#6'_83U;_ -)=%H S*8!0 4 % !0 M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!LW'_$OL([$?+=7HBN[[L8H !) M969'4$@BX<>KPCK&:7Z!L9<$TEM-%/"QCE@=9(W'!5T(93^8Z4PV^1?U.&+= M%?6JA+2^#2+&O"VUPA NK3V".P9/^FZ@K;Y M/D8UW=S7LQFEVC" MK'%&@VQ00QC;%!"G\$:+P!R>I))))>WR#\+%6@"S9VS7EW;6J':9YHXMQX"! MV 9R>RJN6)[ &C;Y!^!)J-RMW>W,Z#;$TI$"]-EO&!%;IS_=@2-?^ TEI\@_ M0I4P-G3Q]B@DU9L"2-C;Z:IQS>%07N0/[MK$P<'_ )ZR0^AI>78%I\C'I@)0 M 4 % !0 4 2P3S6LJ36\LD$L9RDD3%'4]#AE(XQP1W'!H#;Y&H+BPON+V-;& MZ/2^M8L6\C>MW91@!23UDMPN.\3'FEM\@_0GM[:2R9K6]V'3-3"PK>Q,);19 MT):UNXY4XWPN3O0[7$026NF6MO,I26#5]9BD4]F2VT53SW& M1P1P1R*%]P;?(QJ8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &M MI,%N96O;T'[!8>7).%02--*[8MK58V=!(7=2S+O3]W%+\P(!I; M/D.F.EW$ MTL\VHZH\LTC22.=)M,EW)9C_ ,AKCD]!THV^0$7E:-_S_P"I_P#@IM?_ )=4 M :E@NCS))I1OK\K>21&W>;3;:)+:]0[8Y0XU=\"1&:%@0H.]"S*(\@V^0+0S M7M])B=HY+W54>-F1T;2+561T)5E93K7# @@CVH#;RL-\K1O^?_4__!3:_P#R MZH /*T;_ )_]3_\ !3:__+J@"];:=I$D4MW)?ZBMI:E!(7TRVB,[L1BTMG&J MR9N63)^Z0H!9L#J;!^A?M;C3+O6M*:.[OT2&_LH[*S&F6\=O BW49CAWC5W* M@MR\NQV8LSD,3@FR] _0PO*T;_G_ -3_ /!3:_\ RZH /*T;_G_U/_P4VO\ M\NJ -33XM)MX[V^6\U!A;V[6ZL^F6R,DU^LELC1 :NWF2+%Y[@$IC86#94 @ M;?(R_*T;_G_U/_P4VO\ \NJ +%K8Z7=W$5K#?:EYDSA5W:5:JB@ EG=O[:^6 M-$#,S=@I/:C;Y!^!-?2:+.T,,5[J,=M9Q"WMT32[9U(4EI9RS:O&6>:8O(24 M0X8+@!0 +0-OD4?*T;_G_P!3_P#!3:__ "ZH /*T;_G_ -3_ /!3:_\ RZH M/*T;_G_U/_P4VO\ \NJ #RM&_P"?_4__ 4VO_RZH /*T;_G_P!3_P#!3:__ M "ZH /*T;_G_ -3_ /!3:_\ RZH /*T;_G_U/_P4VO\ \NJ #RM&_P"?_4__ M 4VO_RZH UM*C@#R)8WVIM"5!NXY]'L6T_R@?O7@GUOR40=G<@@_=(.*/PL M"T^1Z3'%H/V6 71LI0#\KSA8\O\ 9K091;N9W ^R"RQF1R4\LEFR"4/1?(\- MJA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 .1&=EC12SLP1%499F8 MA54 =220,4 :NI,ELD.E0L&2S9FNG7!6;4' 6<@C[T<*JL"'I^[=A_K#20;? M(R*8!0 =/;'X8Q0&WE8V;X?;;:+5%YF#):ZDHZBY5#Y-V1Z7$2'L,I/W MQE;:=M@_0QJ8%^QLA[EFU&4=&$:DV=HK#MCR[MQ[3@]#R MOT#8R:8&RG_$NTXR?=O-41HX@>&ATU6*S2XZAKF53$I_YYQ2]I :7Z!L8U, MH * "@ H * "@"2**2:1(H8WEE<[4CC5G=F[!44$D_04;?(#5^QV=ASJ4GGW M"]--M)%)1AT%[=KN2$=C'%YDG4,8R*7Z!L6+>Y:]+272I!I&F@7#V-LOE6[R M$A;>WVY+2S32X5I)&=P@D;=A:-@_0@OKB6ZTVUN)FW2S:OK$CD# !:UT4X4? MPJ!@ #@ #I0M/D!BTP"@ H * "@ H * "@ H * "@ H * "@ H * "@ H V M;#_0;>756XE5FM=-!Y_THH#-= '^&VA<$'_GK-">=K87X6#;Y&-3V\K % !0 M 4 :&FW,=O,T5QDV5W&;:\4#)$3,I69%[RPR*DJ>\>.C&EM\@6A*NDS_ &RX MM9'2**T!EN;MN8([48*7"D?ZP2HR&)5YD,B@=>"]@M^!'?7B3!+6T1H-/MS^ MXA;'F2R$!7NKDKP]R^/<(N$7@9(M/D&WE8SJ8&GHG_(9TG_L)V'_ *514@1F M4P)(8GGFB@B&Z2:1(HU]7D8(@X]6(HV^0?@7M6E22_F6(@P6VRSMR. 8+-%M MHG ']]8MY]W)[TEH'Z#-.M4NKC$K&.U@1KB\E7&Z.VBQOV ]978I&@[O*@Z9 MHV!?=8BO;IKRYDN&4(&VK%$OW(((U$<$$8/\$<2H@_W1Y%KN!5&'268QIZ%NE+] M;RL)+ MJ?E1O;Z;#]@MV!21U??>W"'@BYN\*=A'6*(1QXZJQY):WR#;R,L DA5!)) 5 M0,DD\ #OGM3V\K :^I$6D46D1$9M6,M^RD$2:@R[7CR.JVR?N1_M>D@ MV^1%+_R!K#_L)ZM_Z2Z+0!F4P"@ H * "@ H * "@ H * "@ H * "@ H * M"@"S:6LEY5]NYN$C106DED/\ #''&K.Q[*A/:C;Y!^!IZW'+%-#&L M973H(A!ILJLLD$\*$L]PLL3-&TTTI>5P&)4OM/W127W6#;RML8=, H * "@" MU9VDM[,(HMJA07EFD.V&WA3'F3S/_!&H_$G"@%B 5L!OWEQ'?Z8;2Q>4IHY5 MF\S"R:A9C$2WFCY;F?RKO43T*94M:69]/+C?S7']^4 \Q4E^0;&-3 * "@ H * M+]KIT]RAGS';6B';)>7+&.W0]=BD M-+@?ZN)7?_ &<[,Q))^M/;Y ,H V-. LH9=6<#= WD:GF- .032 M\NP+3Y&02222223DD\DD]23ZTP-*7_D#6'_83U;_ -)=%I 9E, H * "@ H M* "@ H * "@ H * "@ H * "@ H V5_XEVG%ONWFJ1E$[&'35?#MCL]S*FP? M],X7[2C*_0-BG:7]Q9!DC*R02']]:3J);6; P#)"W&\#HZ[77^%A1^%@V^1< M^S6%]S8R"QNC_P N%W*!!(3VM+V0@*2>D=P5/82N>*-@_ RYH)K65H9XI()8 MSAHI49'7N,JP!Z8(/IR*8;>5B*@"Q:VLUY.EO NZ1LGDA$1$4L\DCM@)&B*S M,QX 4FC;Y 7KNYAAA_LZP;-N"C7=S@J]_<1Y(;!P4M(V)\J,@?\ /1QN("): M?(-BG9W3V5S%<1A6\LD/&_*31.ICF@D'>.2)G1AZ,: V^1+J-JEK.# 6:SN$ M6YLY&^\8') 1R/\ EK$ZO$_3YHF[$4;?(-BA3 T]$_Y#.D_]A.P_]*HJ0(S* M8&LW^C:/$GW7U&[:9NW^BV"M##_P%KF>YR/6V'H,+\+!L)ID4<#CJPR; M/D9TLLDTDDTK%Y9':21VY9G=BS M,?WR CH * "@"S:VEQ>2>5;1-*X&YL8"1H.LDLC$+%&.[N5 [FEL'Z& MAC3M.^]LU6\7^!2ZZ;"W;P?H5: "@">UMY+NXAMH0#),ZHN3A1GJS-_"B MKEF)X 4D]*-OD!;U*XBDDCM[4G[%8Q_9[8D;3+ABTUTR_P!^:8L_J%*+T04E MH&WR,VF!IR_\@:P_[">K?^DNBT@,RF 4 % !0 4 % !0 4 % !0 4 % !0 4 M % !0!?TZU2YG/G,4M+:-KF\D'!2WC*AE3/_ "UD=DB0=WE7M2V#\+$5Y=/> MW,EPX"[B!'$OW(88U"0P1CM''$J(OLHH6GR JTP"@#4AU-Q$EK?1+?VB#;'' M*Q2XMQ_TZ70!> ?[!WQ'O&3S2M;RL&WR)AI0O"#H\IO,D9LY-D5_#GNT1;;/ M$N>98F( Y=8^@-O(+?@)=3164+Z;9.LC,<:A>ITN67!%K;MU^Q1N,Y_Y:L-Q M&U4 /T#8QJ8!0!LV/^G6DFF'F>(O=::>YD5N:>WR U]41GU"/ M3X 7-DD&F0HO)>:+Y9PN.N^^>X88_P">@^I2T\@_0;J12BPQG^Y"#UPHV\K :_V"VL<-JLK"84TOT#8QJ8!0!IR_\@:P M_P"PGJW_ *2Z+2 S*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '3SZ9?V M^G0V=K:RSR3;;S4C;[9Y(W4,+:TDBA+21"&-FD<.H^>;GB-32_"P6M\CFG1X MV*.C(R\%74JP^JD BF&WD-H * 'QQR32)%$C222,J1QH"S.[$*JJHY))(&*- MOD!LRS+I$;6EG*#?NNR_O(FSY # FQM)%/0%1YLJGYF&Q#L!,B_"P;>0P7]O M>_)JL3&7HNI6RJMV".ANH252] '&1)8F:.2)UDC=3M M9'0AD92.C*P!!]J V\K&GJ<:2B'4[=0L-[N\Z-!A;:_3:;J */NQL66:,?W) M@HR8VI+3Y!L,T3_D,Z3_ -A.P_\ 2J*@$.T=5%X+EUW1:?%+?NIZ$VR[H$(] M'NC!'@\?O*-@6GR);1FLK:;59"?M4[2VVGD\MYK#_3+WG_GE&^Q6_P">DP(_ MU9P>78-C%I@% &I#IC");F^E%A:,-T;2*6N+A?\ ITM00\P/_/1BD?J_:E>W MR#;R'MJ:VR-#I41LXV&U[IF#ZA.N,$-< #[/&PZQ0!!@D,S]:+6^0;&13V\K M % !0 4 % %[3[1;NX"2,8K:%&N+N4#)AM8L&1@#UEL'X6&7UV MU[=Y&:9W:1Y"2',C$ MLS%AW))-/;Y 7DUC4D41M=-<1KP(KQ([Z( ]A'=I(JCZ =:5K>5@V^0[[?9R M_P#'UI5L3_?LI9[&3_OG=+ /P@'XT;>5@V\K"B'2)R%AN;ZT=B L=Q;I=H23 M@#S[5T?.<=+8YS[8)M\@V\C8_LV33(Y8;&XLKK56+1RR1W<,,MC"1@PVT-TT M4INY <2,$#QC,8&2Q!^%A[?(YNXL;RS_ ./FTN+<=C+#)&IST*LR@,#Q@@D& MF+;Y%6@"Q;7=Q92>;:RO"^"K;<%70_>CEC8%98SCE'#*>X-'Z!M\C1W:=?\ M#A-*O#QO16.FS-VWQKN>Q8G^)-\?^Q&.:6WR#\+%"ZLKFR<)<1E PW12*0\, MR#_EI!,A*3)T^9&(['FG^@;?(MZ9+&QETZX8);7X15D;A;:\3/V2YXZ*&9HW M/_/.9SU PMOD"T':3%)!KNF0RH8Y8=6LHI$;@HZ7D:LI]PP(HZ M/D6-/M7D ML&B0JCZI=K;^:_"PV.G(+R^FD /^J5VMG)_Z=FQST-OD&QGZC=) M@>5N"Y'2- SM_"IHV#\+%O[38Z?Q81B\NE_Y?[N(>3&PZ-9V3Y&0>DEQO/0B M.-A0&WR,N:::XD::>5YI7.7DD8NY/NS'-/;RL!%0 4 % !0 4 % &S=?\2^Q MCL!\MS=B*[U#U2,#?969]"J-Y[C^])&#S%PE^0;&-3 * "@#3E_Y UA_V$]6 M_P#271:0&93 * "@ H * "@ H * "@ H * "@ H * )(HI)I(X8D+RR.L<:+ MRS.[!44#U+$"C;RL!HZG+''Y.FVSAK>PW*\B?GWF>K26JV\I^L]@;>1F_VG9C^'%*UO*P;?(/,T:7[]O?61_O6 M\T5W$/\ =@N$B?\ .X/;TY-OD'Z!_9]I+_QZZK:,>T5VDUE+[?,R/ /QGHV\ MK!MY6+EO!K5E$R+:?;[ D-+ NS4;$XSA]]I(X@?&<2QO&_HU'X6#;Y% MD_V=(;>Y!PVF7DBJY8'!6SNF"I.<\"*01R= OF&C8/T-:TBDN=0T>[DC>.]L MM5TRQU2)U*2@KX>16=Q_SRAE/7%+8%I\BA--)/+)/*Y>65VDD=N2SN2S,?Q-/;Y 14 % M!0!IR_\ (&L/^PGJW_I+HM(#\>O^&GOCE_T/'_EM>$/_ )05XOUO$?\ /S_R M6/\ D?Z:_P#$O?A!_P!$C_YE0?\-/?'+_H>/_+:\(?_ "@H^MXC_GY_ MY+'_ "#_ (E[\(/^B1_\RN=?_/(/^&GOCE_T/'_EM>$/_E!1];Q'_/S_ ,EC M_D'_ !+WX0?]$C_YE0?\-/?'+_H>/\ RVO"'_R@H^MXC_GY_P"2Q_R# M_B7OP@_Z)'_S*YU_\\@_X:>^.7_0\?\ EM>$/_E!1];Q'_/S_P EC_D'_$O? MA!_T2/\ YE/_+:\(?\ R@H^MXC_ )^?^2Q_R#_B7OP@ M_P"B1_\ ,KG7_P \@_X:>^.7_0\?^6UX0_\ E!1];Q'_ #\_\EC_ )!_Q+WX M0?\ 1(_^97.O_GD'_#3WQR_Z'C_RVO"'_P H*/K>(_Y^?^2Q_P @_P")>_"# M_HD?_,KG7_SR#_AI[XY?]#Q_Y;7A#_Y04?6\1_S\_P#)8_Y!_P 2]^$'_1(_ M^97.O_GD'_#3WQR_Z'C_ ,MKPA_\H*/K>(_Y^?\ DL?\@_XE[\(/^B1_\RN= M?_/(/^&GOCE_T/'_ );7A#_Y04?6\1_S\_\ )8_Y!_Q+WX0?]$C_ .97.O\ MYY!_PT]\/_ "VO"'_R@H^MXC_GY_Y+'_(/^)>_"#_HD?\ S*YU_P#/ M(FM_VIOCQ:R":#QUY_"!?\TC_YE1#_P -/?'+_H>/_+:\(?\ R@H^MXC_ )^? M^2Q_R#_B7OP@_P"B1_\ ,KG7_P \@_X:>^.7_0\?^6UX0_\ E!1];Q'_ #\_ M\EC_ )!_Q+WX0?\ 1(_^97.O_GD'_#3WQR_Z'C_RVO"'_P H*/K>(_Y^?^2Q M_P @_P")>_"#_HD?_,KG7_SR)8/VI?CM;2QSP^.%62%@\;-X6\&2!67[K;)? M#K*2#R,@X(!'(%'UO$?\_/\ R6/^0?\ $O?A O\ FD=O^IKG7_SQ&/\ M0_' M61VD?QTS.[,[NWAOPBS,[$LS,QT#)8DDDFCZWB%_R\V_NQ_R#_B7OP@_Z)'_ M ,RN=?\ SR&_\-/?'+_H>/\ RVO"'_R@H^MXC_GY_P"2Q_R#_B7OP@_Z)'_S M*YU_\\@_X:>^.7_0\?\ EM>$/_E!1];Q'_/S_P EC_D'_$O?A!_T2/\ YE/_+:\(?\ R@H^MXC_ )^?^2Q_R#_B7OP@_P"B1_\ ,KG7 M_P \AZ?M1?'6)@\7CMXW7[K)X<\(HP^C+H (H^MXC_GY_P"2Q_R#_B7OP@7_ M #2-K?\ 4USK_P">1H?\-;?M!LGER^/Q=+C ^V^$_!%^R@<#:]YX:E9,=MI& M.U'UO$+_ )>6M_=C_D'_ !+WX0+_ )I';_J:YU_\\22/]KS]H>%HV3X@J&A" MK&S>$? TCHB,CI&&D\,L?)22.-ECSL5D5E (!H^MXC_GYM_=C_D'_$O?A O^ M:1V_ZFN=?_/$BN?VMOVA+M95G^(+,)WWS[/"W@J$SL.%$[0^'$,R* BN65 M % H^MXA?\ +S;^['_(/^)>_"#_ *)';_J:YU_\\3-_X:>^.7_0\?\ EM>$ M/_E!1];Q'_/S_P EC_D'_$O?A!_T2/\ YE/_+:\(?\ MR@H^MXC_ )^?^2Q_R#_B7OP@_P"B1_\ ,KG7_P \@_X:>^.7_0\?^6UX0_\ ME!1];Q'_ #\_\EC_ )!_Q+WX0?\ 1(_^97.O_GD'_#3WQR_Z'C_RVO"'_P H M*/K>(_Y^?^2Q_P @_P")>_"#_HD?_,KG7_SR#_AI[XY?]#Q_Y;7A#_Y04?6\ M1_S\_P#)8_Y!_P 2]^$'_1(_^97.O_GD'_#3WQR_Z'C_ ,MKPA_\H*/K>(_Y M^?\ DL?\@_XE[\(/^B1_\RN=?_/(/^&GOCE_T/'_ );7A#_Y04?6\1_S\_\ M)8_Y!_Q+WX0?]$C_ .97.O\ YY$Q_:F^/!MTM?\ A.L01RO,L8\,>#5_>R*B M,[,/#P9SMC4#<3M&=N-QR?6\0O\ EY_Y+'_(/^)>_"#_ *)';_J:YU_\\B'_ M (:>^.7_ $/'_EM>$/\ Y04?6\1_S\_\EC_D'_$O?A!_T2/_ )E_"#_ *)'_P RN=?_ #R# M_AI[XY?]#Q_Y;7A#_P"4%'UO$?\ /S_R6/\ D'_$O?A!_P!$C_YE0?\ M-/?'+_H>/_+:\(?_ "@H^MXC_GY_Y+'_ "#_ (E[\(/^B1_\RN=?_/(E/[4G MQV,,=N?'7[F*6:9$_P"$8\'#;).D"2MN'A[<=RVT(P20-G &3D^MXA?\O/\ MR6/^0?\ $O?A!_T2.W_4USK_ .>1\_5SG[.% !0 4 % !0 4 % !0 4 % !0 M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 G4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__9 end GRAPHIC 5 g786930page1_1.jpg GRAPHIC begin 644 g786930page1_1.jpg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end GRAPHIC 6 g786930page1_2.jpg GRAPHIC begin 644 g786930page1_2.jpg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

R2VLC)+63[-V1\Q6T.T;F)+M\QR6!)/!)//) M-)?D/;Y$P#<)G;WQZ <_T_6C;RL/;Y'V'^QEX(3Q9\9?#8N8?,L='%UKMZ<* MRF.TMY%MP?[H,[J.G3/K5+W?D9R['V=^W5XF2TM/#7AZ+8BV/A_7_$]S;@JJ M.U_)!I>CEHAC'EII^J+GUD;'(Y%HA6V.-_X)I(MI>?$"]:R$$TWAC1H--ED1 M8Y'CN=:\F]G3(#&(O-&T M6@:;=3Z5:2MM&HZY=[K#1;,8(8B6]E#.R99(?,EQB(D"7X"/YZM>UG4O$&M: MKK>I7,UWJ6J7]SJ%_=2X9KF]O9GN+FX<],O)(QP,8SCH*?Z%+3RL<\7!DVD[ M@I)*XQGC.[9SQD8!S^5+;RL&WR,.X58K@)'@RG)=1E<1K\H=AU0#C:#R1P!C ME5MY%+;T(FB'.2 & XP3R"3UZ#KTZT!^A#]GVX/ !X]!R/KZ"C;Y!M\C@O$Z M"/4(AT_T.(\<8S+/CCMQ@U+T^1I'1>AUUF"UOIXX4C3=.'0C<%MQC/TW''UJ MEI;I8AZ7]6;VSRXQD= #T !Y Q^OZ4]OD+]!449\M<_,0!MZY/3'I_\ 7I+\ M@V^1^M'_ 3[\)JL'B_Q7+'L 6WT.VE(QLC!WW>"!G&VW[=W]ZK9?UT,WOZ' M._'*2#QO\4/B!K-\%N[#3I8O">BVKY>)+;PZC6EY(ZDE)4?6SJDD0 VE'60[ MC)D-+06WE8V_V+Y+RU^).OVL8D6"7P?J$4J+C8JQZKH\J,P'W-OE$*?5P/XL MTGHNUA['G7[.X?A[IETSZ-X,6*34TC;,,_B2>W&X28!$GV'3Y%B7 M/*2WEXA&10M/($OP/@UHE;D#9G)W#OD8/!S@CU'IQQ1^A6Q0NR+6(?NPT[L( M[=0P^=SDX)P=L:KDLQSM7/4CE; OR,^.R\H,9',EQ*^Z65@WSMV4 G*QJ.%7 M/ [DDDEK#V\K="1;0L <%=HR#P"""0>GNI &.?UH_0+V^1%#_CXV[_L\*P[R/LYV[MJG&3C&,FFG;IL+E\[%UO&I*[?[-XS MG_C\_,<6H^GTHOY6L+DMUV)8/'"PR1O_ &3N$;(VS[?MSM(."19GKCT-'-;I ML')YV^1]P_ __@H%!\%? Z^$+;X.KKMR;^YU";5V\??V6LTLJJL2MIZ^"KHA M8]B$_P"E'=@_=W4?!W6?&&OM\/(_% M&J>)=&MM)L'F\5G2K70S;W-Q=F1;:/PU=&\@DF>U+0K):L1:G,I:3K?%N]UO4K_5]3TV2[U'4[RYU"^NY-2S-<7EY,]Q=3R-]@_UD MD\CN3ZFCFMTM8/9VZ[>10'Q("XQHN,?]1'' ]OL'7D_X4?).^D;G8*B8O\ :(8EVG8H^Q'YF9 MSMUV\BB_CDR"?.F$-*$"L+[&Q5R2 /LG.YL$\C[H%+FMT!0M;7;R./U"]^W3 =K-Y?E;8Q'MW^9G#NV=VQ?[^,8[4OT+2Y=.Q__]D! end GRAPHIC 7 g786930page1_3.jpg GRAPHIC begin 644 g786930page1_3.jpg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